My Size (MYSZ) 10-K 19 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 01, 2020	Jun. 30, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	My Size, Inc.
Entity Central Index Key	0001211805
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Entity Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Document Fiscal Period Focus	FY
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE
Entity File Number	001-37370
Entity Public Float			$ 16,746,829
Entity Common Stock, Shares Outstanding		2,600,701

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents		$ 1,203	$ 5,140
Restricted cash		263	90
Restricted deposit			181
Short-term deposit			1,209
Accounts receivable		38
Other receivables and prepaid expenses		321	218
Total current assets		1,825	6,838
Property and equipment, net		141	71
Right-of-use assets		966
Investment in marketable securities		26	208
Total noncurrent assets		1,133	279
Total assets		2,958	7,117
Current liabilities:
Operating lease liabilities		102
Trade payables		440	295
Accounts payable		378	276
Warrants and derivatives		328	1,252
Total current liabilities		1,248	1,823
Operating lease liabilities		659
Total non-current liabilities		659
CONTINGENCIES AND COMMITMENTS
Total Liabilities		1,907	1,823
SHAREHOLDERS' EQUITY
Stock capital - Common stock of $ 0.001 par value - Authorized: 100,000,000 and 50,000,000 shares; Issued and outstanding: 1,992,243 and 1,990,159, respectively	[1]	2	2
Additional paid-in capital		30,102	29,144
Accumulated other comprehensive loss		(539)	(835)
Accumulated deficit		(28,514)	(23,017)
Total shareholders' equity		1,051	5,294
Total liabilities and shareholders' equity		$ 2,958	$ 7,117
[1]	Adjusted to give retroactive effect of 1:15 Reverse stock split, see note 10 (b)

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	50,000,000
Common stock, shares issued	1,992,243	1,990,159
Common stock, shares outstanding	1,992,243	1,990,159

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenues		$ 63
Cost of revenues		(21)
Gross profit		42
Operating expenses
Research and development		(1,516)	(1,105)
Sales and marketing	[1]	(1,929)	(899)
General and administrative	[1]	(2,587)	(3,171)
Total operating expenses		(6,032)	(5,175)
Operating loss		(5,990)	(5,175)
Financial income (expense), net		493	(794)
Net loss		(5,497)	(5,969)
Other comprehensive income (loss):
Foreign currency translation differences		296	(701)
Total comprehensive loss		$ (5,201)	$ (6,670)
Basic loss per share	[2]	$ (2.75)	$ (3.03)
Diluted loss per share	[2]	$ (3.12)	$ (3.03)
Basic and diluted weighted average number of shares outstanding		1,999,222	1,941,139
[1]	Certain prior period amounts have been reclassified to conform with current year presentation.
[2]	Adjusted to give retroactive effect of 1:15 Reverse stock split, see note 10 (b)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Common stock		Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	Total
Balance at Dec. 31, 2017	$ 2		$ 16,028	$ (134)	$ (17,048)	$ (1,152)
Balance, shares at Dec. 31, 2017	1,482,583
Effect of early adoption of ASU 2018-07			$ 284			$ 284
Balance as of January 1, 2018	$ 2
Balance as of January 1, 2018, shares	1,482,583		16,312	(134)	(17,048)	(868)
Stock-based compensation related to options granted to employees and consultants			$ 149			$ 149
Issuance of shares to consultants		[1]	384			384
Issuance of shares to consultants, shares	22,910
Total comprehensive loss				(701)	(5,969)	(6,670)
Exercise of warrants and options		[1]	8,648			8,648
Exercise of warrants and options, shares	263,842
Liability reclassified to equity		[1]	104			104
Liability reclassified to equity, shares	5,491
Issuance and receipts on account of shares, net of issuance cost of $351		[1]	3,547			3,547
Issuance and receipts on account of shares, net of issuance cost of $351, shares	215,333
Balance at Dec. 31, 2018	$ 2		29,144	(835)	(23,017)	5,294
Balance, shares at Dec. 31, 2018	1,990,159
Stock-based compensation related to options granted to employees and consultants			644			644
Issuance of shares to consultants		[1]	48			48
Issuance of shares to consultants, shares	2,084
Issuance of shares, net of issuance cost of $138		[1]	266			266
Issuance of shares, net of issuance cost of $138, shares	87,756
Reverse Stock Split (Note 10 (b)		[1]					[1]
Reverse Stock Split (Note 10 (b), Shares	5,901
Total comprehensive loss				296	(5,497)	(5,201)
Balance at Dec. 31, 2019	$ 2		$ 30,102	$ (539)	$ (28,514)	$ 1,051
Balance, shares at Dec. 31, 2019	2,085,900
[1]	Represents an amount of less than $1.

Consolidated Statements of Sh_2

Consolidated Statements of Shareholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement of Stockholders' Equity [Abstract]
Issuance of cost net		$ 351
Issuance of shares net	138

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (5,497)	$ (5,969)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	30	31
Change in right to use asset	7
Revaluation of warrants and derivatives and stock-based compensation liabilities	(997)	1,632
Interest payment of short-term loan		(192)
Interest and revaluation of short-term deposit	55	(113)
Interest received on short-term deposits	16	18
Revaluation of investment in marketable securities	195	(123)
Capital loss on disposal of property and equipment	8
Stock based compensation - equity	692	533
Stock based compensation - liability		469
Change in embedded derivative		(59)
Increase in accounts receivable	(37)
Decrease (increase) in other receivables and prepaid expenses	(83)	142
Increase in trade payables	117	71
Increase (decrease) in accounts payables	76	(37)
Net cash used in operating activities	(5,418)	(3,597)
Cash flows from investing activities:
Proceeds from (investment in) short-term deposits, net	1,200	(1,200)
Proceeds from (investment in) restricted deposits, net	181	(181)
Investment in right to use asset	(205)
Purchase of property and equipment	(103)	(40)
Net cash provided by (used in) investing activities	1,073	(1,421)
Cash flows from financing activities:
Proceeds from exercise of warrants and options		3,945
Proceeds from issuance of shares, warrants and short-term loan, net	266	5,649
Repayment of short term loan, net of issuance costs		(554)
Net cash provided by financing activities	266	9,040
Effect of exchange rate fluctuations on cash and cash equivalents	315	(664)
Increase (Decrease) in cash and cash equivalents and restricted cash	(3,764)	3,358
Cash and cash equivalents and restricted cash at the beginning of the year	5,230	1,872
Cash and cash equivalents and restricted cash at the end of the year	1,466	5,230
Non cash activities:
Exercise of warrants and stock-based compensation to equity		4,703
stock-based compensation liability reclassified to equity		284
Derivative liability reclassified to equity		$ 104

General

General	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 - GENERAL a. My Size, Inc. is developing unique measurement technologies based on algorithms with applications in a variety of areas, from the apparel e-commerce market, to the courier services market and to the Do It Yourself ("DIY") smartphone and tablet apps market. The technology is driven by proprietary algorithms, which are able to calculate and record measurements in a variety of novel ways. The Company has two subsidiaries, My Size Israel 2014 Ltd. ("My Size Israel") and Topspin Medical (Israel) Ltd., both of which are incorporated in Israel. References to the Company include the subsidiaries unless the context indicates otherwise. My Size, Inc., was incorporated and commenced operations in September 1999, as Topspin Medical Inc. ("Topspin"), a private company registered in the State of Delaware. In December 2013, the Company changed its name to Knowledgetree Ventures Inc. Subsequently, in February 2014, the Company changed its name to My Size, Inc. Topspin was engaged, through its Israeli subsidiary, in research and development in the field of cardiology and urology. Since September 1, 2005, the Company has traded on the Tel Aviv Stock Exchange ("TASE"). Between 2007 and 2012 the Company reported as a public company with the U.S. Securities and Exchange Commission (the "SEC"). In August 2012, the Company suspended its reporting obligations under Section 13(a) and 15(d) of the Securities Exchange Act of 1934. In mid-2015, the Company resumed reporting as a public company. b. On January 9, 2014, at the Company's general meeting of shareholders, its shareholders approved an engagement with one of the Company's investors (the "Seller") for the purchase of rights in a Venture (the "Venture"), including the rights to the method and the certain patent application that had been filed by the Seller (the "Assets"). The Venture relates to the development of technologies and applications which will assist the consumer to take his or her body measurements accurately using a mobile device to ensure the purchase of clothing with the best possible fit without the need to try them on. In February 2014, the Company established a wholly-owned subsidiary, My Size (Israel) 2014 Ltd., a company registered in Israel, which is currently engaged in the development of the Venture described above. In return for purchasing an interest in the Venture, the Company undertook to pay the Seller 18% of the Company's operating profit, direct or indirect, connected to the Venture for a period of seven years starting from the end of the Venture's development period. As part of the agreement, the Seller received an option to buy back the Assets for consideration which will reflect the market fair value at that time, on the occurrence of the following events: a) if a motion is filed to liquidate the Company; b) if seven years after signing the agreement, the Company's total accumulated revenues, direct or indirect, from the Venture or the commercialization of the patent will be lower than NIS 3.6 million. In such an event, Seller may repurchase the interest in the Venture at a market price to be determined by an independent third party valuation consultant, who shall be chosen by agreement by the parties, and the audit committee shall conduct the negotiations on behalf of the Company to determine the identity of the consultant. c. On July 25, 2016, the Company's common stock began publicly trading on the Nasdaq Capital Market under the symbol "MYSZ". The Company's shares of common stock are listed both on the Nasdaq Capital Market and TASE. d. Since inception, the Company has incurred significant losses and negative cash flows from operations and has an accumulated deficit of $28,514. The Company has financed its operations mainly through fundraising from various investors. The Company's management expects that the Company will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected cash flows and cash balances as of December 31, 2019, management is of the opinion that its existing cash will be sufficient to fund operations until the end of August 2020. As a result, there is substantial doubt about the Company's ability to continue as a going concern. Management's plans include the continued commercialization of the Company's products and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to cease operations. The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern. e. The Company operates in one reportable segment and all of its long-lived assets are located in Israel.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). a. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. b. Financial statements in U.S. dollars: The currency of the primary economic environment in which the operations of the Company and its subsidiary are conducted is the New Israeli Shekel ("NIS") and thus it is the Company's and its subsidiary functional currency. The reporting currency according to which these financial statements are prepared is the U.S. dollar. The financial statements are translated as follows: 1. Assets and liabilities at the end of each reporting period (including comparative data) are translated at the closing rate at the end of the reporting period. 2. Income and expenses for each period included in profit or loss (including comparative data) are translated at average exchange rates for the relevant periods; however, if exchange rates fluctuate significantly, income and expenses are translated at the exchange rates at the date of the transactions. 3. Stock capital, capital reserves and other changes in capital are translated at the exchange rate prevailing at the date of incurrence. 4. Accumulated deficit is translated based on the opening balance translated at the exchange rate at that date and other relevant transactions during the year are translated as described in 2) and 3) above. 5. All resulting translation adjustments are recognized as a separate component of accumulated other comprehensive loss in equity The Company reassessed its functional currency and determined to change its functional currency to the U.S. dollar from the NIS as of January 1, 2020. The change in functional currency will be accounted for prospectively from such date. In 2019, the Company went through a strategic shift which involved a significant change in its business model, that clearly indicates that the functional currency has changed, beginning January 2020. In previous years, the Company acted as a platform to fund its operational subsidiary, My Size Israel, which conducts its research and development activities in NIS. Accordingly, the Company has not been substantially focused on its operating activities for that period. By the end of 2018, the Company transitioned to a new business model (B2B2C) and concluded that the main market that the Company should focus on would be the apparel market in the US. Consequently, the Company established marketing and distribution channels in the US along with having a new pricing model denominated in USD. Throughout 2019, the Company itself hired sales personnel which are based in the US and signed agreements with customers for which it began generating revenue in USD for the first time since it began its operations. Accordingly, by the end of 2019, the Company is no longer considered a 'holding company' for the matter of determining its functional currency under ASC 830 based on the currency of its operating entities. As a result of being an operational company that enters into operational agreements and generates revenues on an ongoing basis, the management of the Company has concluded that as of January 1 2020, the currency that most faithfully portrays the economic results of the Company's operations is the U.S. dollar beginning January 1 2020. My Size Israel functional currency remains the NIS. c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation. d. Cash equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date acquired. e. Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets, at the following annual rates: % Computers and peripheral equipment 33 Office furniture and equipment 7-15 Leasehold improvements Over the term of the lease or the useful life of the improvements, whichever is shorter f. Impairment of long-lived assets: The Company's property and equipment are reviewed for impairment in accordance with ASC 360, "Property Plant and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2019 and 2018, no impairment losses have been recorded. g. Severance pay: The Subsidiary's liability for severance pay is covered by Section 14 of the Israeli Severance Pay Law ("Section 14"). Under Section 14, employees in Israel are entitled to have monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf to their insurance funds. Payments in accordance with Section 14 exempt the Subsidiary from any additional obligation for these employees. As a result, the Subsidiary does not recognize any liability for severance pay due to these employees and the deposits under Section 14 are not recorded as an asset in the Subsidiary's balance sheet. These contributions for compensation represent defined contribution plans and expenses are recorded based on actual deposits. h. Research and development costs: Research and development costs are charged to the statement of operations, as incurred. Most of the research and development expenses are for wages and subcontractors. i. Income taxes: The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Companies' tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized. The Company establishes a valuation allowance, if necessary, to reduce deferred tax assets to the amount more likely than not to be realized. As of December 31, 2019, and 2018, a full valuation allowance was established by the Company. The Company implements a two-step approach to recognize and measure the benefit of its tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is greater than 50 percent (cumulative basis) likely to be realized upon settlement. The Company believes that its tax positions are all highly certain of being upheld upon examination. As such, as of December 31, 2019 and 2018 the Company has not recorded a liability for unrecognized tax benefits. j. Accounting for stock-based compensation: The Company accounts for its employees' stock-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company estimates stock option grant date fair value using the Binomial option pricing-model. The Company recorded stock options issued to non-employees at the grant date fair value, and recognizes expenses over the related service period by using the straight-line attribution approach. All awards are equity classified. On June 20, 2018, the FASB issued ASU 2018-07, Stock Compensation: Improvements to Nonemployee Stock-Based Payment Accounting, to align the guidance for stock compensation to employees and nonemployees, which replaces ASC 505-50, Equity-Equity-Based Payments to Non-Employees. The Company elected to early adopt the guidance as of October 1, 2018. The ASU affected the measurement and classification of the stock-based payments to consultants in the Company's financial statements. The fair value of each agreement at the adoption date is being considered as the new fair value of the stock-based payments to consultants and the expenses will be recognized over the remaining service period. Furthermore, as of the adoption date, stock-based payments to consultants were classified as equity. The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends. The risk-free interest rate for grants with an exercise price denominated in USD for employees and several consultants is based on the yield from US treasury zero-coupon bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. k. Fair value of financial instruments: ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price. In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company's own credit risk. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends. The Company holds share certificates in iMine Corporation ("iMine") formerly known as Diamante Minerals, Inc., a publicly-traded company on the OTCQB. Due to sales restrictions on the sale of the iMine share, the fair value of the shares was measured on the basis of the quoted market price for an otherwise identical unrestricted equity instrument of the same issuer that trades in a public market, adjusted to reflect the effect of the sales restrictions and is therefore, ranked as Level 2 asset. l. Basic and diluted net loss per share: Basic net loss per share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net income per share is computed based on the weighted average number of shares of common stock outstanding during each year plus dilutive potential equivalent common stock considered outstanding during the year, in accordance with ASC 260, "Earnings per Share". For the years ended December 31, 2019 and 2018, all outstanding options and warrants have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive. As described in Note 10a, for accounting purposes, the loss per share amounts have been adjusted to give retroactive effect to the Exchange Ratio and the Reverse Stock Split for all periods presented in these consolidated financial statements. m. Concentrations of credit risk: Financial instruments that potentially subject the Company and its subsidiaries to concentrations of credit risk consist principally of cash and cash equivalents. Cash and cash equivalents and short term deposits are invested in banks in Israel and United States. Such deposits in Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. The Company and its subsidiaries have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. n. Revenue from contracts with customers: The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU 2014-09), an updated standard on revenue recognition and issued subsequent amendments to the initial guidance in March 2016, April 2016, May 2016 and December 2016 within ASU 2016-08, 2016-10, 2016-12 and 2016-20, respectively (collectively, "ASC 606"). The core principle of the new standard is for companies to recognize revenue to depict the transfer of services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. In addition, the new standard requires expanded disclosures. The Company has adopted the standard effective January 1, 2018. The reported results for the year ended December 31, 2019 reflect the application of ASC 606 guidance. To recognize revenue under ASC 606, the Company applies the following five steps: 1. Identify the contract with a customer. A contract with a customer exists when the Company enters into an enforceable contract with a customer and the Company determines that collection of substantially all consideration for the services is probable. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. The transaction price is determined based on the consideration to which the Company will be entitled in exchange for providing the service to the customer. 4. Allocate the transaction price to performance obligations in the contract. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. 5. Recognize revenue when or as the Company satisfies a performance obligation. When the Company provides a service, revenue is recognized over the service term. The Company's revenue is derived from the sale of cloud-enabled software subscriptions, associated software maintenance and support. Revenue is recognized when a contract exists between the Company and a customer (business) and upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which may be capable of being distinct and accounted for as separate performance obligations. In case of offerings such as cloud-enabled subscription, other service elements in the contract are generally delivered concurrently with the subscription services and therefore revenue is recognized in a similar manner as the subscription services. Product, Subscription and Services Offerings Such performance obligations includes cloud-enabled subscriptions, software maintenance, training and technical support. Fully hosted subscription services (SaaS) allow customers to access hosted software during the contractual term without taking possession of the software. Cloud-hosted subscription services are sold on a fee-per-subscription that is based on consumption or usage (per fit recommendation). We recognize revenue ratably over the contractual service term for hosted services that are priced based on a committed number of transactions where the delivery and consumption of the benefit of the services occur evenly over time, beginning on the date the services associated with the committed transactions are first made available to the customer and continuing through the end of the contractual service term. Over-usage fees and fees based on the actual number of transactions are billed in accordance with contract terms as these fees are incurred and are included in the transaction price of an arrangement as variable consideration. Fees based on a number of transactions or impressions per month, are allocated to the period in which the transactions occur. Revenue for subscriptions sold as a fee per period is recognized ratably over the contractual term as the customer simultaneously receives and consumes the benefit of the underlying service. o . Impact of recently adopted accounting standard: In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). ASU 2016-02 is intended to increase transparency and comparability of accounting for lease transactions. For all leases with terms greater than twelve months, the new guidance requires lessees to recognize right-of-use assets and corresponding lease liabilities on the balance sheet and to disclose qualitative and quantitative information about lease transactions. The new standard maintains a distinction between finance leases and operating leases. As a result, the effect of leases in the statement of operations and statement of cash flows is largely unchanged. ASU 2016-02 is effective starting January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, to allow a company to elect an optional modified retrospective transition method that applies the new lease requirements through a cumulative-effect adjustment in the period of adoption. Effective as of January 1, 2019, the Company adopted the new lease accounting standard using the modified retrospective transition option of applying the new standard at the adoption date. The Company leases include an office space lease agreement for 36 months, with an option to extend for an additional 36 months and 36 months cancelable operating lease agreements on behalf of personnel vehicles. The lease term includes a non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. For the office rent lease the Company has elected to account for the lease and non-lease maintenance components as a single lease component. Therefore, the lease payments used to measure the lease liability include all of the fixed consideration in the contract, including in-substance fixed payments, owed over the lease term. Adoption of the new standard resulted in the recording of operating lease right-to-use assets and operating lease liabilities on the Company's consolidated balance sheets, but did not have an impact on the Company's beginning balance of retained earnings, consolidated statement of operations or statement of cash flows. The most significant impact was the recognition of right-to-use assets and lease liabilities on account of the Company's operating leases. The Company recognized $127 of right of use assets and operating lease liabilities at January 1, 2019. In addition, the right-of-use assets include leasehold improvements. See also note 6. p. Contingencies and Commitments Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. q . Derivative instruments The Company accounts for its derivative instruments as either assets or liabilities and measures them at fair value through profit or loss.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
CASH AND CASH EQUIVALENTS	NOTE 3 - CASH AND CASH EQUIVALENTS The Company's cash and cash equivalents balance at December 31, 2019 and 2018 is denominated in the following currencies: December 31, 2019 2018 US Dollars 806 4,879 Euro 47 4 New Israeli Shekels 350 257 1,203 5,140

Other Receivables and Prepaid E

Other Receivables and Prepaid Expenses	12 Months Ended
	Dec. 31, 2019
Other Receivables and Prepaid Expenses [Abstract]
OTHER RECEIVABLES AND PREPAID EXPENSES	NOTE 4 - OTHER RECEIVABLES AND PREPAID EXPENSES December 31, 2019 2018 Prepaid expenses and deferred costs 268 130 Government authorities 40 27 Insurance reimbursement - 50 Other 13 11 321 218

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 5 - PROPERTY AND EQUIPMENT, NET Computers Office Leasehold Total Cost Balance as at January 1, 2018 98 20 17 135 Additions 32 8 - 40 Translation adjustments (10 ) - (2 ) (12 ) Balance as at December 31, 2018 120 28 15 163 Balance as at January 1, 2019 120 28 15 163 Additions 26 22 55 103 Disposals - - (16 ) (16 ) Translation adjustments 10 2 1 13 Balance as at December 31, 2019 156 52 55 263 Accumulated Depreciation Balance as at January 1, 2018 60 3 5 68 Additions 27 2 2 31 Translation adjustments (6 ) - (1 ) (7 ) Balance as at December 31, 2018 81 5 6 92 Balance as at January 1, 2019 81 5 6 92 Additions 24 3 3 30 Disposals - - (8 ) (8 ) Translation adjustments 7 - 1 8 Balance as at December 31, 2019 112 8 2 122 Carrying amounts As at December 31, 2018 39 23 9 71 As at December 31, 2019 44 44 53 141

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
LEASES	NOTE 6 - LEASES In August 2019, the Company entered into an office space lease agreement. The lease term is for 36 months beginning on August 20, 2019 and ending on August 20, 2022, with an option to extend for an additional 36 months. Monthly rent payments including utilities amounting to approximately NIS 39,000 per month. In addition, The Company entered into a three-year cancelable operating lease agreement for cars. Approximate future minimum remaining rental payments due under these leases are as follows: Year Ending: 2020 $ 135 2021 $ 150 2022 $ 154 2023 $ 162 2024 $ 162 2025 $ 112 Rent expense (excluding taxes, fees and other charges) for the year ended December 31, 2019 totaled approximately $174. The Company has entered into operating leases primarily for an office space lease agreement. These leases generally have terms which range from 1 year to 6 years, and often include one or more options to renew. These renewal terms can extend the lease term from 1 year to 6 years, and are included in the lease term when it is reasonably certain that the Company will exercise the option. These operating leases are included in "Right of use assets" on the Company's December 31, 2019 consolidated balance sheets, and represent the Company's right to use the underlying asset for the lease term. The Company's obligations to make lease payments are included in the current liabilities as "Operating lease liabilities" and in the non-current liabilities as "Operating lease liabilities - long term" on the Company's December 31, 2019 consolidated balance sheets. Based on the present value of the lease payments for the remaining lease term of the Company's existing leases, the Company recognized right-of-use assets and operating lease liabilities of approximately $127 on January 1, 2019. Operating lease right-of-use assets and liabilities commencing after January 1, 2019 are recognized at commencement date based on the present value of lease payments over the lease term. As of December 31, 2019, right-of-use assets and operating lease liabilities were $761. In addition, the right-of-use assets include payments for leasehold improvements of $205. Right-of-use assets include the capitalization of improvements (net of amortization) amounting to $205. Total right-of-use assets as of December 31, 2019 amount to $966. The Company recorded a decrease in right to use asset of $7 for the year ended December 31, 2019. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The interest rate used to discount future lease payment was 8.69%. Maturities of lease liabilities as of December 31, 2019 were as follows (in thousands): Due in a 12-month period ended December 31, 2020 164 2021 172 2022 162 2023 186 2024 172 2025 115 Thereafter 971 Less imputed interest: (210 ) Total lease liabilities 761

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 7 - RELATED PARTY TRANSACTIONS A. Balances with related parties: The following related party payables are included in trade payables and accounts payable. December 31, 2019 2018 Officers (*) 28 26 Directors 13 11 Monkeytech (**) - 3 41 40 (*) The amount includes the net salary payable. (**) The former Chief Technology Officer of the Company, Oded Shoshan, was compensated pursuant to a technology consulting agreement between the Company and Monkeytech Ltd. Mr. Shoshan was the chief executive officer up until April 2019 as well as one of the owners of Monkeytech. B. Related parties benefits: Year ended 2019 2018 Salaries and related expenses 904 792 Share based payments 473 101 Directors 45 57 Research and development expenses to subcontractor - 164 1,422 1,114

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS	NOTE 8 - FINANCIAL INSTRUMENTS The following tables presents the Company's significant assets and liabilities that are measured at fair value on recurring basis and their classification within the fair value hierarchy: December 31, 2019 Fair value hierarchy Level 1 Level 2 Level 3 Financial assets Investment in marketable securities - 26 - December 31, 2019 Fair value hierarchy Level 1 Level 2 Level 3 Financial liabilities Warrants and derivative - 328 - December 31, 2018 Fair value hierarchy Level 1 Level 2 Level 3 Financial assets Investment in marketable securities - 208 - December 31, 2018 Fair value hierarchy Level 1 Level 2 Level 3 Financial liabilities Warrants derivative - 1,252 - The carrying amounts of cash and cash equivalents, restricted cash, restricted deposit, short term deposit, accounts receivable, other receivables and prepaid expenses, trade payable and accounts payable approximate their fair value due to the short-term maturities of such instruments. At December 31, 2019, the recognized gain (loss) and fair value (based on quoted market prices with a discount due to security- restrictions on IMine shares) of the marketable securities were ($192) and $26, respectively (at December 31, 2018 $123 and $208, respectively).

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
TAXES ON INCOME	NOTE 9 - TAXES ON INCOME a. At December 31, 2019, the Company had U.S. federal net operating loss carryforwards of approximately $20,262 available to reduce future taxable income. Utilization of the U.S. net operating losses may be subject to substantial limitations due to the change of ownership provisions of the Internal Revenue Code of 1986. The U.S. Company has final tax assessments through 2012. On December 22, 2017, the Tax Reform Act was signed into law. The legislation significantly changes U.S. tax law by, among other things, lowering the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. As a result of the decrease in the corporate income tax rate, the Company revalued the ending net deferred tax assets at December 31, 2017, but did not recognize any incremental income tax expense in 2017 due to the revaluation of the valuation allowance. b. Foreign tax: 1. Tax rates: Presented hereunder are the tax rates relevant to the Company's Israeli subsidiaries: 2019 - 23% 2018 - 23% On December 22, 2016, the Knesset plenum passed the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018) – 2016, by which, inter alia, the corporate tax rate would be reduced from 25% to 23% in two steps. The first step was to a rate of 24% as of January 2017 and the second step was to a rate of 23% as of January 2018. 2. The Company's subsidiaries have estimated total available carryforward operating tax losses for Israeli income tax purposes of approximately $53,028 as of December 31, 2019. Of these losses, a total of $43,614 are owned by Topspin Medical (Israel) Ltd. Topspin tax losses may be offset only by future income with respect to the same operational activity by which it was incurred for an indefinite period of time. The other losses are owned by My Size Israel 2014 Ltd and may be carryforward to offset against future income for an indefinite period of time. 3. Topspin Medical (Israel) Ltd. has final tax assessments through 2013 and My Size (Israel) 2014 Ltd. has final tax assessments through 2014. c. U.S. and foreign components of loss from continuing operations, before income taxes consisted of: December 31, 2019 2018 U.S (896 ) (4,131 ) Non-U.S. (foreign) (4,601 ) (1,838 ) (5,497 ) (5,969 ) d. Deferred taxes: Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are as follows: December 31, 2019 2018 Deferred tax assets: Operating loss carryforwards 16,451 14,380 Warrants and options 89 60 Marketable securities 375 336 Other temporary differences 295 212 Deferred tax assets before valuation allowance 17,210 14,988 Valuation allowance (17,210 ) (14,988 ) Net deferred tax asset - - The following table presents a reconciliation of the beginning and ending valuation allowance: December 31, 2019 2018 Balance at beginning of the year 14,988 14,835 Additions in valuation allowance to the income statement 1,211 876 Reductions in valuation allowance due to exchange rate differences and change in tax rate 1,011 (723 ) Balance at end of the year 17,210 14,988 In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance at December 31, 2019 and 2018. e. Theoretical tax The following presents the adjustment between the theoretical tax amount and the tax amount included in the financial statements: December 31, 2019 2018 Loss before income taxes 5,497 5,969 Statutory tax rate 21 % 21 % Computed "expected" tax expense 1,154 1,253 Foreign tax rate differences and exchange rate differences 77 38 Nondeductible expenses (20 ) (415 ) Change in valuation allowance (1,211 ) (876 ) Taxes on income - -

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
SHAREHOLDERS' EQUITY	NOTE 10 - SHAREHOLDERS' EQUITY a. Common stock confers upon their holders the right to receive notice to participate and vote in general meetings of the Company, and the right to receive dividends if declared. b. On November 18, 2019, the Company announced that the Board approved a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). Upon the Reverse Stock Split every fifteen shares of the Company's issued and outstanding common stock is automatically converted into one share of common stock, without any change in the par value per share. In addition, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options and warrants entitling the holders to purchase common stock. Any fraction of a share of common stock that would otherwise have resulted from the Reverse Stock Split was rounded up to the next whole number. For accounting purposes, all share and per share amounts for common stock, warrants stock, options stock and loss per share amounts reflect the Reverse Stock Split for all periods presented in these financial statements. Any fractional shares that resulted from the Reverse Stock Split were rounded up to the nearest whole share. c. On December 22, 2017, the Company completed a public offering of 255,500 shares of its common stock to the public at $9.75 per share and five-year warrants to purchase an aggregate of 191,628 shares of common stock at an exercise price of $12.765 per share. Total consideration from the public offering was $2,490. The proceeds net of issuance costs were $2,130. The common stock and warrants are accounted for as two different components. Warrants exercisable into shares of common stock are recognized as a liability and measured at fair value. Changes in fair value are recorded in the statements of comprehensive loss. The warrants were measured at fair value and accounted for $1,625, and the residual net amount of $505 was recorded in equity. As of December 31, 2019 and 2018, the warrants were presented in the balance sheet at fair value of $34 and $124, respectively. The warrants include anti-dilution price protection, in the event that the Company will issue additional shares of common stock or common stock equivalents at a price lower than the exercise price of the warrants. In addition, upon the Company's entering into an agreement to issue securities that are issuable at a price which varies or may vary with the market price of the Company's common stock (the "Variable Price"), the holder of the warrant may elect to adjust the exercise price of the warrants to the Variable Price of the securities sold by the Company pursuant to the agreement. During the year ended December 31, 2018, warrants to purchase 176,995 shares of the Company's common stock were exercised for proceeds to the Company of $2,260. Upon the exercise of the warrants, the Company reclassified the liabilities associated with the warrants to equity in the total amount of $3,851. During November, 2019, pursuant to the anti-dilution adjustment provisions in outstanding warrants to purchase 14,633 shares of common stock of the Company, the per share exercise price was reduced to $4.1, after giving effect to the one-for-fifteen reverse stock split effected on November 18, 2019, following the issuance of shares of common stock under the Company's at-the-market offering program. The following table sets forth the assumptions used to measure the fair value of the warrants using the Monte Carlo Model: Day of issuance As of December 31 st Fair Value 1,625 33 Strike Price $ 12.765 $ 4.1 Dividend Yield % - - Expected volatility 89.5 % 94.3 % Risk free rate 2.26 % 1.64 % Expected term 5 2.98 Stock Price $ 10.65 $ 3.32 d . On February 2, 2018, the Company conducted a public offering of its securities pursuant to which it issued an aggregate of 200,000 shares of its common stock and five-year warrants to purchase up to 100,013 shares of common stock at an exercise price of $39.75 per share for gross proceeds of $6,000. The Company received net proceeds of $5,464 after deducting placement agent fees and other offering expenses. The common stock and warrants are accounted for as two different components. Warrants exercisable into shares of common stock are recognized as a liability and measured at fair value. Changes in fair value are recorded in the statements of comprehensive loss. The warrants were measured at a total fair value of $2,102, and the residual net amount of $3,547 was recorded in the equity. As of December 31, 2019 and 2018, the warrants were presented in the balance sheet at a fair value of $231 and $862, respectively. The warrants include anti-dilution price protection in the event that the Company issues additional shares of common stock or common stock equivalents at a price lower than the exercise price of the warrants, subject to customary exceptions. In addition, upon the Company's entering into an agreement to issue securities that are issuable at a price which varies or may vary with the market price of the Company's common stock (the "Variable Price"), the holder of the warrant may elect to adjust the exercise price of the warrants to the Variable Price of the securities sold by the Company pursuant to the agreement. During November 2019, pursuant to the anti-dilution adjustment provisions in outstanding warrants to purchase 100,013 shares of common stock of the Company, the per share exercise price was reduced to $4.1, after giving effect to the one-for-fifteen reverse stock split effected on November 18, 2019, following the issuance of shares of common stock under the Company's at-the-market offering program. The following table sets forth the assumptions used to measure the fair value of the warrants using the Monte Carlo Model: Day of issuance As of December 31 st Fair Value 2,102 231 Strike Price $ 39.75 $ 4.1 Dividend Yield % - - Expected volatility 96.7 % 93.6 % Risk free rate 2.59 % 1.65 % Expected term 5 3.09 Stock Price $ 25.35 $ 3.32 e . On September 13, 2019, the Company entered into an At the Market Offering Agreement ("ATM") with HC Wainwright. According to the agreement, the Company may offer and sell, from time to time, its shares of common stock having an aggregate offering price of up to $5.5 million through HC Wainwright, or the ATM Prospectus Supplement. From September 13, 2019 until December 31, 2019, the Company issued 87,756 shares of common stock at an average price of $4.77 per share through the ATM Prospectus, resulting in net proceeds of $418. The Company paid a commission equal to 3% of the gross proceeds from the sale of our shares of common stock under the ATM Prospectus. On January 15, 2020, the Company terminated the ATM Prospectus, but the Sales agreement remains in full force and effect. The common stock is accounted for under equity, resulting in an increase of $266 after deducting legal and other related expenses. f. A summary of the warrant activity during the years ended December 31, 2019 and 2018 is presented below: Number of Weighted Weighted Outstanding, December 31, 2017 268,329 16.5 Issued 100,013 Expired or exercised (224,065 ) Outstanding, December 31, 2018 144,277 31.5 4.06 Issued - - Expired or exercised - - Outstanding, December 31, 2019 144,277 4.1 (*) 3.06 Exercisable, December 31, 2019 144,277 4.1 (*) 3.06 As of December 31, 2019, and 2018, the warrants that were issued during the year ended December 31, 2018, were deemed to be a derivative liability. (*) Pursuant to the anti-dilution adjustment provisions in outstanding warrants, the per share exercise price was reduced to $4.1, following the issuance of shares of common stock under the Company's at-the-market offering program.

Stock Based Compensation

Stock Based Compensation	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
STOCK BASED COMPENSATION	NOTE 11 - STOCK BASED COMPENSATION The stock-based expense recognized in the financial statements for services received is related to Research and Development, Sales and Marketing and General and Administrative expenses as shown in the following table: Year ended 2019 2018 Stock-based compensation expense - Research and development 161 50 Stock-based compensation expense - Sales and marketing 179 3 Stock-based compensation expense - General and administrative 352 949 692 1,002 The allocation of the stock-based expenses between equity and liability recorded in the financial statements is as shown in the following table: Year ended 2019 2018 Stock-based compensation expense - equity awards 692 533 Stock-based compensation expense - liability awards - 469 692 1,002 Options issued to consultants a. In December 2016, the Company engaged a consultant ("Consultant2") to provide services to the Company with respect to marketing strategy and public relations, including potential investor relations. The share based cost recognized during the year 2019 and 2018, including the cost associated with the consulting service attributed to the reporting period and the revaluation of the options amounted to $0 and $549, respectively. In addition, in 2018, an amount of $203 was classified to equity following the adoption of ASU 2018-07, see also Note 2 j. b. In April 2017, the Company engaged a consultant ("Consultant3") to provide services to the Company with respect to financing and strategic advisory for a period of two years. For such consulting services, the Company agreed to pay a monthly retainer and agreed to issue to Consultant3 3,334 shares of the Company common stock and 2,084 shares each quarter thereafter. During 2019 and 2018, the Company issued 10,417 shares of common stock to Consultant3 each year. During the years 2019 and 2018, costs in the sum of $48 and $192, respectively, were recorded as a stock-based compensation expense - relating to equity awards. c. In July 2017, the Company engaged a consultant ("Consultant4") to provide services to the Company with respect to business consulting for a period of one year. For such consulting services, the Company issued to Consultant4 10,000 stock options to purchase up to 10,000 shares of the Company's common stock at an exercise price of $30 per share. The options vest in four equal installments on a quarterly basis and terminate 18 months from each vesting date. During the year 2018, costs in sum $70 were recorded as stock-based liability- awards. In addition, in 2018, an amount of $7 was classified to equity following the adoption of ASU 2018-07, see also note 2 j. As of December 31, 2019, the options were not exercised and expired. d. In August 2017, the Company engaged a consultant ("Consultant5") to provide services to the Company with respect to various services including corporate planning, financial public relations, business strategy and shareholders relations. For such consulting services, the Company agreed to issue to Consultant5 options to purchase 66,667 shares of the Company's common stock at an exercise prices of $15.00 per share exercisable until April 30, 2018 and 15,334 options to purchase common stock at exercise price of $37.5 per share exercisable until December 31, 2018. The board approved the issuance on August 31, 2017. In January 23, 2018, the Company and Consultant5 entered into an amendment to the consulting agreement pursuant to which the number of the options and the exercise prices of the options were amended to 53,334 options at $15.00 per share exercisable until July 23, 2018. The options were not exercised and expired on July 23, 2018. e. In January 2018, the Company entered into a twelve-month agreement with a consultant ("Consultant6") to provide strategic consulting and investor relations services. Pursuant to the terms of the agreement, the Company agreed to pay a monthly fee of $5 and to issue to Consultant6 6,600 shares of common stock of the Company in three tranches of 2,200 each, with each tranche vesting on the first day of January, April and August 2018. The board approved the issuance on February 14, 2018. In February 2018, the Company issued 6,600 shares of common stock to Consultant6. During 2019 and 2018, an amount of $0 and $112 was recorded as a stock-based equity award with respect to Consultant6. f. In February 2018, the Company entered into an agreement with a consultant ("Consultant7") to provide consulting services relating to investor relations. Pursuant to the agreement and in consideration for such services, the Company agreed to issue to Consultant7 4,334 shares of common stock of the Company. Under the agreement, the shares vested as follows: 3,334 shares shall vest upon the effective date of the agreement and 1,000 shares shall vest three months after the effective date of the agreement. The board approved the issuance on February 14, 2018. In February 2018, the Company issued 3,334 shares of common stock to Consultant 7 and in May 2018, the Company issued 1,000 shares of common stock to Consultant7. During 2019 and 2018, an amount of $0 and $77, respectively was recorded by the Company as a stock-based expense equity - awards with respect to Consultant7. g. In October 2017, the Company entered into agreements with three consultants (collectively, the "Consultants") to provide services to the Company including promoting the Company's products and services. For such consulting services, the Company agreed to issue to each of the Consultants options to purchase up to 3,334 shares of the Company's common stock at an exercise price of $30.00 per share. The options vest quarterly in four equal installments and terminate eighteen (18) months from their respective vesting dates. The issuance of the options under the agreement was subject to the increase in the number of shares of the Company's common stock reserved for issuance pursuant to the Company's 2017 Consultant Plan. The increase in reserve pursuant to the Company's 2017 Consultant Plan was approved by the Company's stockholders on February 12, 2018 at the Company's special meeting of stockholders. During 2019 and 2018, an amount of $0 and $73 was recorded by the Company as a stock-based liability- awards and stock-based equity awards, with respect to the Consultants. In addition, in 2018, an amount of $60 was classified to equity following the adoption of ASU 2018-07, see also Note 2 j. h. In February 2018, the Company entered into an agreement with a consultant ("Consultant8") to provide services to the Company including improving the Company's products and services. Pursuant to such agreement and in consideration for such consulting services, the Company agreed to issue to Consultant8 options to purchase up to 367 shares of the Company's common stock at an exercise price of $21.15 per share. The options are fully vested and shall terminate five years after the grant date. During 2019 and 2018, amount of $0 and $5 was recorded by the Company as a stock-based liability- awards, with respect to Consultant8. In addition, in 2018, an amount of $4 was classified to equity following the adoption of ASU 2018-07, see also Note 2 j. i. In February 2018, the Company entered into an agreement with a consultant ("Consultant9") to provide services to the Company including marketing and improving the implementation of the technology with potential customers. Pursuant to such agreement and in consideration for such consulting services, the Company agreed to issue to Consultant9 options to purchase up to 1,000 shares of the Company's common stock at an exercise price of $30 per share. The options shall vest quarterly in three equal installments and shall terminate five years after the grant date. During 2019 and 2018, amounts of $0 and $4 were recorded by the Company as stock-based liability-awards and amounts of $0 and $1 as a stock-based equity awards respectively, with respect to Consultant9. In addition, in 2018, an amount of $7 was classified to equity following the adoption of ASU 2018-07, see also note 2 j. j. In August 2018, the Company entered into an agreement with a consultant ("Consultant10") to provide services to the Company including promoting the Company's products and services. Pursuant to such agreement and in consideration for such consulting services, the Company agreed to issue to Consultant10 options to purchase up to 3,334 shares of the Company's common stock at an exercise price of $15.00 per share. The options shall vest quarterly in eight equal installments and shall terminate five years after the grant date. The board approved the issuance on August 15, 2018. During 2019 and 2018, amounts of $22 and $2 were recorded by the Company as stock-based liability-awards and amounts of $0 and $6 stock-based expense equity awards respectively, with respect to Consultant10. In addition, in 2018, an amount of $3 was classified to equity following the adoption of ASU 2018-07, see also note 2 j. k. In December 2018, the Company entered into an agreement with a consultant ("Consultant11") to provide services to the Company including promoting the Company's products and services. Pursuant to such agreement and in consideration for such consulting services, the Company agreed to issue to Consultant11 options to purchase up to 3,334 shares of the Company's common stock at an exercise price of $11.325 per share. The options shall vest quarterly in four equal installments and shall terminate five years after the grant date. The board approved the issuance on December 27, 2018. During 2019 and 2018, an amount of $29 and $1 was recorded by the Company as a stock-based equity-awards with respect to Consultant11. l. In January 2019, the Company entered into an agreement with a consultant ("Consultant12") to provide services to the Company including promoting the Company's products and services via potential sources of media. Pursuant to said agreement and in partial consideration for such consulting services, the Company agreed to issue to Consultant12 a warrant to purchase up to 3,334 shares of the Company's common stock upon execution of the agreement and after six months, a further warrant to purchase 6,667 shares of the Company's common stock. The warrants are exercisable at $15.00 per share and have a term of 12 months from the date of issuance. During 2019, an amount of $42 was recorded by the Company as stock-based equity awards with respect to Consultant12. m. In April 2019, the Company entered into a twelve month agreement with a consultant ("Consultant13") to provide services to the Company including assisting the Company to promote, market and sell the Company's technology to potential customers. Pursuant to said agreement and in partial consideration for such consulting services, the Company agreed to issue to Consultant13 options to purchase up to 2,667 shares of the Company's common stock upon execution of the agreement. The options are exercisable at $15.00 per share and shall vest in 4 equal installments every three months starting July 2019. Unexercised options shall expire 2 years from the effective date. During 2019, an amount of $8 was recorded by the Company as stock-based equity awards with respect to Consultant13. n. In July 2019, the Company entered into a three year agreement with a consultant ("Consultant14") to provide services to the Company including assisting the Company to promote, market and sell the Company's technology to potential customers. Pursuant to such agreement and in partial consideration for such consulting services, the Company agreed to issue to Consultant14 options to purchase up to 2,667 shares of the Company's common stock upon execution of the agreement. The options are exercisable at $15.00 per share and shall vest in 3 equal installments every twelve months starting July 2019. Unexercised options shall expire 4 years from the effective date. During 2019, an amount of $3 was recorded by the Company as stock-based equity awards with respect to Consultant14. The Company's outstanding options granted to consultants as of December 31, 2019 are as follows: Issuance date Options for Weighted Options Expiration April 2012 3,068 NIS 2.25 3,068 April 2022 September 2014 4,000 NIS 24 4,000 September 2020 September 2014 2,334 NIS 30 2,334 September 2020 May 2017 66,667 USD 64 66,667 March 2019- October 2017 5,001 USD 30 5,001 July 2019- February 2018 1,367 USD 27.6 1,367 May 2021- August 2018-December 2018 13,335 USD 14.1 5,419 August 2023- January-June 2019 10,000 USD 15 10,000 January 2020-July 2020 July 2019 5,334 USD 15 1,333 April 2021-July 2023 Total 111,106 99,189 The Company uses the Black & Scholes model to measure the fair value of the stock options with the assistance of a third party valuation. The fair value of the Company's stock options granted to non-employees was calculated using the following weighted average assumptions: Year ended Year ended 2019 2018 Dividend yield 0 % 0 % Expected volatility 68.9%-94.4 % 84%-102 % Risk-free interest 1.81- 2.56 % 2.02%-2.97 % Contractual term of up to (years) 1-4 1.1-5 Stock Option Plan for employees In March 2017, the Company adopted a stock option plan (the "Plan") pursuant to which the Company's Board of Directors may grant stock options to officers and key employees. The total number of options which may be granted to directors, officers, employees under this plan, is limited to 200,000 options. Stock options can be granted with an exercise price equal to or less than the stock's fair market value at the date of grant. The fair value of each option award is estimated on the date of grant using the Binomial option-pricing model that used the weighted average assumptions in the following table. The risk free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. 2019 2018 Dividend yield 0 % 0 % Expected volatility 85.2%-86.33 88.43 % Risk-free interest 1.82-2.13 3.04 % Contractual term of up to (years) 4.95-5.01 4.7-5 Suboptimal exercise multiple (NIS) 5 5 In the years ending December 31, 2019 and 2018, 103,601 and 10,635 options, respectively, were granted. The total stock option compensation expense in the year ending December 31, 2019 amounted to $540 as follows: R&D expenses amounted to $161, S&M expenses amounted to $168 and General and administrative expenses amounted to $211. The total stock option compensation expense in the year ending December 31, 2018 amounted to $139 as follows: R&D expenses amounted to $50, S&M expenses amounted to $3 and General and administrative expenses amounted to $86. As of December 31, 2019, there was a total of $737 unrecognized compensation cost relating to non-vested share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 2.75 years. Share option activity during 2019 is as follows: 2019 Number of Weighted Outstanding at January 1 68,637 $ 17.4 Granted 103,601 11.33 Exercised - Expired (8,334 ) Outstanding at year end 163,904 13.87 Vested at year end 101,116 15.43 Share option activity during 2018 is as follows: 2018 Number of Weighted Outstanding at January 1 61,703 18.15 Granted 10,635 13.65 Exercised (1,778 ) Expired (1,923 ) Outstanding at year end 68,637 $ 17.4 Vested at year end 54,889 $ 18.15

Short Term Loan

Short Term Loan	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
SHORT TERM LOAN	NOTE 12 - SHORT TERM LOAN On October 26, 2017, the Company entered into a loan agreement with certain accredited investors in a private placement transaction for total consideration of $1,200. The Company was required to repay a principal amount of $1,333 and to issue 59,264 warrants to purchase up to 59,264 shares of the Company's common stock. The warrants and loan are accounted for as two different components. As of December 31, 2019 and 2018, the warrants were measured at fair value of $63 and $257, respectively. Changes in fair value of the warrants are recorded in the statement of comprehensive loss. During February 2018, the Company repaid the remaining outstanding balance and recorded financial expenses in an amount of $192 During 2018, warrants to purchase 29,633 shares of the Company's common stock were exercised, respectively, for total proceeds to the Company of $318. Upon the exercise of the warrants, the Company reclassified the liabilities associated with the warrants to equity in the total amount of $411. During November, 2019, pursuant to the anti-dilution adjustment provisions in outstanding warrants to purchase 29,633 shares of common stock of the Company, the per share exercise price was reduced to $4.1, after giving effect to the one-for-fifteen reverse stock split effected on November 18, 2019, following the issuance of shares of common stock under the Company's at-the-market offering program. The following table sets forth the assumptions used to measure the fair value of the warrants using the Monte Carlo Model Day of issuance As of December 31 st As of December 31 st Fair Value $ 523 $ 257 $ 63 Strike Price $ 11.25 $ 10.725 $ 4.1 Dividend Yield % - - - Expected volatility 86.73 % 88.96 % 87.12 % Risk free rate 2.11 % 2.51 % 1.64 % Expected term 5 3.8 2.8 Stock Price $ 11.25 $ 11.55 $ 3.32

Contingencies and Commitments

Contingencies and Commitments	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES AND COMMITMENTS	NOTE 13 - CONTINGENCIES AND COMMITMENTS a. On August 7, 2018, the Company commenced an action against North Empire LLC ("North Empire") in the Supreme Court of the State of New York, County of New York for breach of a Securities Purchase Agreement (the "Agreement") in which it is seeking damages in an amount to be determined at trial, but in no event less than $616,000. On August 2, 2018, North Empire filed a Summons with Notice against the Company, also in the same Court, in which they allege damages in an amount of $11.4 million arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by the Company against them, alleging that the Company failed to deliver stock certificates to North Empire causing damage to North Empire in the amount of $10,958,589. North Empire also filed a third-party complaint against the Company's CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, the Company filed a reply to North Empire's counterclaims. On November 15, 2018, the Company's CEO and now former Chairman of the Board filed a motion to dismiss North Empire's third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint. The parties are now engaging in discovery in connection with the claims and counterclaims. The Company believes it is more likely than not that the counterclaims will be denied. b. On January 22, 2019, the Company was notified by the Nasdaq Stock Market, LLC ("Nasdaq") that the Company was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The notification provided that the Company had 180 calendar days, or until July 22, 2019, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The Company did not regain compliance with the Rule by July 22, 2019 and, as a result, on July 23, 2019, the Company received notice from the Staff that, based upon the Company's continued non-compliance with the Rule, the Staff had determined to delist the Company's common stock from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the "Panel"). The hearing occurred on September 19, 2019. On October 1, 2019, the Panel granted the Company's request for continued listing of the Company's common stock on the Nasdaq Capital Market pursuant to an extension through January 20, 2020, subject to the condition that the Company regain compliance with the Bid Price Rule by such date and that the Company demonstrate compliance with all requirements for continued listing on the Nasdaq. Previously, on August 5, 2019, at the annual meeting of the Company's stockholders, discretionary authority was granted to the Company's board of directors to effect a reverse stock split at any time until August 5, 2020 at a ratio within the range from one for two up to one for thirty. on November 19, 2019, the Company received formal notice from Nasdaq that the Company's non-compliance with the minimum $2.5 million stockholders' equity requirement, as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Rule"), as of September 30, 2019, could serve as an additional basis for delisting. In accordance with the Nasdaq Listing Rules, the Company has been granted the opportunity and plans to timely present its plan to regain compliance with the Stockholders' Equity Rule for the Panel's consideration. On February 7, 2020, the Company received the formal decision of the (Panel), in which the Panel determined that the Company has evidenced full compliance with the minimum $1.00 per share bid price requirement, and granted the Company's request for continued listing on Nasdaq pursuant to an extension, through May 18, 2020, to demonstrate compliance with the minimum $2.5 million stockholders' equity requirement. As previously disclosed, on November 19, 2019, the Company received formal notice from Nasdaq that it did not satisfy the Stockholders' Equity Rule as of September 30, 2019. In response, the Company requested a hearing before the Panel to present its plan to regain compliance with the rule. The Panel's February 7, 2020 decision follows such hearing.

Sales and Marketing

Sales and Marketing	12 Months Ended
	Dec. 31, 2019
Sales and Marketing [Abstract]
SALES AND MARKETING	NOTE 14 - SALES AND MARKETING Year ended December 31, 2019 2018 Salaries 582 163 Consultants and subcontractors 434 218 Marketing 480 144 Share based payments for consultants and employees 179 3 Travel 99 284 Other 155 87 1,929 899

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Dec. 31, 2019
General And Administrative Expenses [Abstract]
GENERAL AND ADMINISTRATIVE EXPENSES	NOTE 15 - GENERAL AND ADMINISTRATIVE EXPENSES Year ended December 31, 2019 2018 Salaries 554 617 Professional services 721 813 Share based payments for consultants, directors and employees 352 949 Rent, office expenses and communication 285 194 Insurance 296 149 Travel 66 144 Directors 45 57 Other 268 248 2,587 3,171

Financial Income (Expense), Net

Financial Income (Expense), Net	12 Months Ended
	Dec. 31, 2019
Financial Income Expense Net [Abstract]
FINANCIAL INCOME (EXPENSE), NET	NOTE 16 - FINANCIAL INCOME (EXPENSE), NET Year ended A. Financial income December 31, 2019 2018 Revaluation of derivative 8 156 Exchange rate differences - 706 Revaluation investment in marketable securities - 123 Change in fair value of warrants 989 - Other 51 28 1,048 1,013 Year ended B. Financial expense December 31, 2019 2018 Exchange rate differences 357 - Financial expenses from loans - 192 Change in fair value of warrants - 1,587 Revaluation investment in marketable securities 195 - Other 3 28 555 1,807

Events Subsequent to the Balanc

Events Subsequent to the Balance Sheet	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
EVENTS SUBSEQUENT TO THE BALANCE SHEET	NOTE 17 EVENTS SUBSEQUENT TO THE BALANCE SHEET a. On January 15, 2020, the Company conducted a public offering of its securities pursuant to which it issued 514,801 shares of its common stock and warrants to purchase up to 514,801 shares of common stock at an exercise price of $3.76 per share for gross proceeds of $2,000. The term of the warrants are five and a half years. The Company received net proceeds of $1,700 after deducting placement agent fees and other offering expenses. b. In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. While initially the outbreak was largely concentrated in China, it has now spread to several other countries, including Israel, and infections have been reported globally. Many countries around the world, including in Israel, have significant governmental measures being implemented to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people, and other material limitations on the conduct of business. These measures have resulted in work stoppages and other disruptions. The extent to which the coronavirus impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. In particular, the continued spread of the coronavirus globally, could adversely impact our operations and workforce, including our marketing and sales activities and ability to raise additional capital, which in turn could have an adverse impact on our business, financial condition and results of operation.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Use of estimates	a. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Financial statements in U.S. dollars:	b. Financial statements in U.S. dollars: The currency of the primary economic environment in which the operations of the Company and its subsidiary are conducted is the New Israeli Shekel ("NIS") and thus it is the Company's and its subsidiary functional currency. The reporting currency according to which these financial statements are prepared is the U.S. dollar. The financial statements are translated as follows: 1. Assets and liabilities at the end of each reporting period (including comparative data) are translated at the closing rate at the end of the reporting period. 2. Income and expenses for each period included in profit or loss (including comparative data) are translated at average exchange rates for the relevant periods; however, if exchange rates fluctuate significantly, income and expenses are translated at the exchange rates at the date of the transactions. 3. Stock capital, capital reserves and other changes in capital are translated at the exchange rate prevailing at the date of incurrence. 4. Accumulated deficit is translated based on the opening balance translated at the exchange rate at that date and other relevant transactions during the year are translated as described in 2) and 3) above. 5. All resulting translation adjustments are recognized as a separate component of accumulated other comprehensive loss in equity The Company reassessed its functional currency and determined to change its functional currency to the U.S. dollar from the NIS as of January 1, 2020. The change in functional currency will be accounted for prospectively from such date. In 2019, the Company went through a strategic shift which involved a significant change in its business model, that clearly indicates that the functional currency has changed, beginning January 2020. In previous years, the Company acted as a platform to fund its operational subsidiary, My Size Israel, which conducts its research and development activities in NIS. Accordingly, the Company has not been substantially focused on its operating activities for that period. By the end of 2018, the Company transitioned to a new business model (B2B2C) and concluded that the main market that the Company should focus on would be the apparel market in the US. Consequently, the Company established marketing and distribution channels in the US along with having a new pricing model denominated in USD. Throughout 2019, the Company itself hired sales personnel which are based in the US and signed agreements with customers for which it began generating revenue in USD for the first time since it began its operations. Accordingly, by the end of 2019, the Company is no longer considered a 'holding company' for the matter of determining its functional currency under ASC 830 based on the currency of its operating entities. As a result of being an operational company that enters into operational agreements and generates revenues on an ongoing basis, the management of the Company has concluded that as of January 1 2020, the currency that most faithfully portrays the economic results of the Company's operations is the U.S. dollar beginning January 1 2020. My Size Israel functional currency remains the NIS.
Principles of consolidation:	c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.
Cash equivalents:	d. Cash equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date acquired.
Property and equipment:	e. Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets, at the following annual rates: % Computers and peripheral equipment 33 Office furniture and equipment 7-15 Leasehold improvements Over the term of the lease or the useful life of the improvements, whichever is shorter
Impairment of long-lived assets:	f. Impairment of long-lived assets: The Company's property and equipment are reviewed for impairment in accordance with ASC 360, "Property Plant and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2019 and 2018, no impairment losses have been recorded.
Severance pay:	g. Severance pay: The Subsidiary's liability for severance pay is covered by Section 14 of the Israeli Severance Pay Law ("Section 14"). Under Section 14, employees in Israel are entitled to have monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf to their insurance funds. Payments in accordance with Section 14 exempt the Subsidiary from any additional obligation for these employees. As a result, the Subsidiary does not recognize any liability for severance pay due to these employees and the deposits under Section 14 are not recorded as an asset in the Subsidiary's balance sheet. These contributions for compensation represent defined contribution plans and expenses are recorded based on actual deposits.
Research and development costs:	h. Research and development costs: Research and development costs are charged to the statement of operations, as incurred. Most of the research and development expenses are for wages and subcontractors.
Income taxes:	i. Income taxes: The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Companies' tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized. The Company establishes a valuation allowance, if necessary, to reduce deferred tax assets to the amount more likely than not to be realized. As of December 31, 2019, and 2018, a full valuation allowance was established by the Company. The Company implements a two-step approach to recognize and measure the benefit of its tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is greater than 50 percent (cumulative basis) likely to be realized upon settlement. The Company believes that its tax positions are all highly certain of being upheld upon examination. As such, as of December 31, 2019 and 2018 the Company has not recorded a liability for unrecognized tax benefits.
Accounting for stock-based compensation:	j. Accounting for stock-based compensation: The Company accounts for its employees' stock-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company estimates stock option grant date fair value using the Binomial option pricing-model. The Company recorded stock options issued to non-employees at the grant date fair value, and recognizes expenses over the related service period by using the straight-line attribution approach. All awards are equity classified. On June 20, 2018, the FASB issued ASU 2018-07, Stock Compensation: Improvements to Nonemployee Stock-Based Payment Accounting, to align the guidance for stock compensation to employees and nonemployees, which replaces ASC 505-50, Equity-Equity-Based Payments to Non-Employees. The Company elected to early adopt the guidance as of October 1, 2018. The ASU affected the measurement and classification of the stock-based payments to consultants in the Company's financial statements. The fair value of each agreement at the adoption date is being considered as the new fair value of the stock-based payments to consultants and the expenses will be recognized over the remaining service period. Furthermore, as of the adoption date, stock-based payments to consultants were classified as equity. The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends. The risk-free interest rate for grants with an exercise price denominated in USD for employees and several consultants is based on the yield from US treasury zero-coupon bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
Fair value of financial instruments:	k. Fair value of financial instruments: ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price. In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company's own credit risk. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends. The Company holds share certificates in iMine Corporation ("iMine") formerly known as Diamante Minerals, Inc., a publicly-traded company on the OTCQB. Due to sales restrictions on the sale of the iMine share, the fair value of the shares was measured on the basis of the quoted market price for an otherwise identical unrestricted equity instrument of the same issuer that trades in a public market, adjusted to reflect the effect of the sales restrictions and is therefore, ranked as Level 2 asset.
Basic and diluted net loss per share:	l. Basic and diluted net loss per share: Basic net loss per share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net income per share is computed based on the weighted average number of shares of common stock outstanding during each year plus dilutive potential equivalent common stock considered outstanding during the year, in accordance with ASC 260, "Earnings per Share". For the years ended December 31, 2019 and 2018, all outstanding options and warrants have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive. As described in Note 10a, for accounting purposes, the loss per share amounts have been adjusted to give retroactive effect to the Exchange Ratio and the Reverse Stock Split for all periods presented in these consolidated financial statements.
Concentrations of credit risk:	m. Concentrations of credit risk: Financial instruments that potentially subject the Company and its subsidiaries to concentrations of credit risk consist principally of cash and cash equivalents. Cash and cash equivalents and short term deposits are invested in banks in Israel and United States. Such deposits in Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. The Company and its subsidiaries have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Revenue from contracts with customers:	n. Revenue from contracts with customers: The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU 2014-09), an updated standard on revenue recognition and issued subsequent amendments to the initial guidance in March 2016, April 2016, May 2016 and December 2016 within ASU 2016-08, 2016-10, 2016-12 and 2016-20, respectively (collectively, "ASC 606"). The core principle of the new standard is for companies to recognize revenue to depict the transfer of services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. In addition, the new standard requires expanded disclosures. The Company has adopted the standard effective January 1, 2018. The reported results for the year ended December 31, 2019 reflect the application of ASC 606 guidance. To recognize revenue under ASC 606, the Company applies the following five steps: 1. Identify the contract with a customer. A contract with a customer exists when the Company enters into an enforceable contract with a customer and the Company determines that collection of substantially all consideration for the services is probable. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. The transaction price is determined based on the consideration to which the Company will be entitled in exchange for providing the service to the customer. 4. Allocate the transaction price to performance obligations in the contract. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. 5. Recognize revenue when or as the Company satisfies a performance obligation. When the Company provides a service, revenue is recognized over the service term. The Company's revenue is derived from the sale of cloud-enabled software subscriptions, associated software maintenance and support. Revenue is recognized when a contract exists between the Company and a customer (business) and upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which may be capable of being distinct and accounted for as separate performance obligations. In case of offerings such as cloud-enabled subscription, other service elements in the contract are generally delivered concurrently with the subscription services and therefore revenue is recognized in a similar manner as the subscription services. Product, Subscription and Services Offerings Such performance obligations includes cloud-enabled subscriptions, software maintenance, training and technical support. Fully hosted subscription services (SaaS) allow customers to access hosted software during the contractual term without taking possession of the software. Cloud-hosted subscription services are sold on a fee-per-subscription that is based on consumption or usage (per fit recommendation). We recognize revenue ratably over the contractual service term for hosted services that are priced based on a committed number of transactions where the delivery and consumption of the benefit of the services occur evenly over time, beginning on the date the services associated with the committed transactions are first made available to the customer and continuing through the end of the contractual service term. Over-usage fees and fees based on the actual number of transactions are billed in accordance with contract terms as these fees are incurred and are included in the transaction price of an arrangement as variable consideration. Fees based on a number of transactions or impressions per month, are allocated to the period in which the transactions occur. Revenue for subscriptions sold as a fee per period is recognized ratably over the contractual term as the customer simultaneously receives and consumes the benefit of the underlying service.
Impact of recently adopted accounting standard:	o . Impact of recently adopted accounting standard: In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). ASU 2016-02 is intended to increase transparency and comparability of accounting for lease transactions. For all leases with terms greater than twelve months, the new guidance requires lessees to recognize right-of-use assets and corresponding lease liabilities on the balance sheet and to disclose qualitative and quantitative information about lease transactions. The new standard maintains a distinction between finance leases and operating leases. As a result, the effect of leases in the statement of operations and statement of cash flows is largely unchanged. ASU 2016-02 is effective starting January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, to allow a company to elect an optional modified retrospective transition method that applies the new lease requirements through a cumulative-effect adjustment in the period of adoption. Effective as of January 1, 2019, the Company adopted the new lease accounting standard using the modified retrospective transition option of applying the new standard at the adoption date. The Company leases include an office space lease agreement for 36 months, with an option to extend for an additional 36 months and 36 months cancelable operating lease agreements on behalf of personnel vehicles. The lease term includes a non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. For the office rent lease the Company has elected to account for the lease and non-lease maintenance components as a single lease component. Therefore, the lease payments used to measure the lease liability include all of the fixed consideration in the contract, including in-substance fixed payments, owed over the lease term. Adoption of the new standard resulted in the recording of operating lease right-to-use assets and operating lease liabilities on the Company's consolidated balance sheets, but did not have an impact on the Company's beginning balance of retained earnings, consolidated statement of operations or statement of cash flows. The most significant impact was the recognition of right-to-use assets and lease liabilities on account of the Company's operating leases. The Company recognized $127 of right of use assets and operating lease liabilities at January 1, 2019. In addition, the right-of-use assets include leasehold improvements. See also note 6.
Contingencies and Commitments	p. Contingencies and Commitments Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Derivative instruments	q . Derivative instruments The Company accounts for its derivative instruments as either assets or liabilities and measures them at fair value through profit or loss.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of property and equipment annual rate	% Computers and peripheral equipment 33 Office furniture and equipment 7-15 Leasehold improvements Over the term of the lease or the useful life of the improvements, whichever is shorter

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Schedule of cash and cash equivalent balance	December 31, 2019 2018 US Dollars 806 4,879 Euro 47 4 New Israeli Shekels 350 257 1,203 5,140

Other Receivables and Prepaid_2

Other Receivables and Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Other Receivables and Prepaid Expenses [Abstract]
Schedule of other receivables and prepaid expenses	December 31, 2019 2018 Prepaid expenses and deferred costs 268 130 Government authorities 40 27 Insurance reimbursement - 50 Other 13 11 321 218

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	Computers Office Leasehold Total Cost Balance as at January 1, 2018 98 20 17 135 Additions 32 8 - 40 Translation adjustments (10 ) - (2 ) (12 ) Balance as at December 31, 2018 120 28 15 163 Balance as at January 1, 2019 120 28 15 163 Additions 26 22 55 103 Disposals - - (16 ) (16 ) Translation adjustments 10 2 1 13 Balance as at December 31, 2019 156 52 55 263 Accumulated Depreciation Balance as at January 1, 2018 60 3 5 68 Additions 27 2 2 31 Translation adjustments (6 ) - (1 ) (7 ) Balance as at December 31, 2018 81 5 6 92 Balance as at January 1, 2019 81 5 6 92 Additions 24 3 3 30 Disposals - - (8 ) (8 ) Translation adjustments 7 - 1 8 Balance as at December 31, 2019 112 8 2 122 Carrying amounts As at December 31, 2018 39 23 9 71 As at December 31, 2019 44 44 53 141

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Schedule of future minimum remaining rental payments	Year Ending: 2020 $ 135 2021 $ 150 2022 $ 154 2023 $ 162 2024 $ 162 2025 $ 112
Schedule of maturities of lease liabilities	Due in 12 month period ended December 31, 2020 164 2021 172 2022 162 2023 186 2024 172 2025 115 Thereafter 971 Less imputed interest: (210 ) Total lease liabilities 761

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Schedule of related party payables	December 31, 2019 2018 Officers (*) 28 26 Directors 13 11 Monkeytech (**) - 3 41 40
Schedule of controlling shareholder benefits	Year ended 2019 2018 Salaries and related expenses 904 792 Share based payments 473 101 Directors 45 57 Research and development expenses to subcontractor - 164 1,422 1,114

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of significant assets and liabilities that are measured at fair value on recurring basis	December 31, 2019 Fair value hierarchy Level 1 Level 2 Level 3 Financial assets Investment in marketable securities - 26 - December 31, 2019 Fair value hierarchy Level 1 Level 2 Level 3 Financial liabilities Warrants and derivative - 328 - December 31, 2018 Fair value hierarchy Level 1 Level 2 Level 3 Financial assets Investment in marketable securities - 208 - December 31, 2018 Fair value hierarchy Level 1 Level 2 Level 3 Financial liabilities Warrants derivative - 1,252 -

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of tax rates relevant to the Company's Israeli subsidiary	2019 - 23% 2018 - 23%
Schedule of U.S. and foreign components of loss from continuing operations, before income taxes	December 31, 2019 2018 U.S (896 ) (4,131 ) Non-U.S. (foreign) (4,601 ) (1,838 ) (5,497 ) (5,969 )
Schedule of deferred tax assets	December 31, 2019 2018 Deferred tax assets: Operating loss carryforwards 16,451 14,380 Warrants and options 89 60 Marketable securities 375 336 Other temporary differences 295 212 Deferred tax assets before valuation allowance 17,210 14,988 Valuation allowance (17,210 ) (14,988 ) Net deferred tax asset - -
Schedule of reconciliation of the beginning and ending valuation allowance	December 31, 2019 2018 Balance at beginning of the year 14,988 14,835 Additions in valuation allowance to the income statement 1,211 876 Reductions in valuation allowance due to exchange rate differences and change in tax rate 1,011 (723 ) Balance at end of the year 17,210 14,988
Schedule of adjustment between the theoretical tax amount and the tax amount included in the financial statements	December 31, 2019 2018 Loss before income taxes 5,497 5,969 Statutory tax rate 21 % 21 % Computed "expected" tax expense 1,154 1,253 Foreign tax rate differences and exchange rate differences 77 38 Nondeductible expenses (20 ) (415 ) Change in valuation allowance (1,211 ) (876 ) Taxes on income - -

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of assumptions used to measure fair value	Day of issuance As of December 31 st Fair Value 1,625 33 Strike Price $ 12.765 $ 4.1 Dividend Yield % - - Expected volatility 89.5 % 94.3 % Risk free rate 2.26 % 1.64 % Expected term 5 2.98 Stock Price $ 10.65 $ 3.32 Day of issuance As of December 31 st Fair Value 2,102 231 Strike Price $ 39.75 $ 4.1 Dividend Yield % - - Expected volatility 96.7 % 93.6 % Risk free rate 2.59 % 1.65 % Expected term 5 3.09 Stock Price $ 25.35 $ 3.32
Schedule of warrant activity	Number of Weighted Weighted Outstanding, December 31, 2017 268,329 16.5 Issued 100,013 Expired or exercised (224,065 ) Outstanding, December 31, 2018 144,277 31.5 4.06 Issued - - Expired or exercised - - Outstanding, December 31, 2019 144,277 4.1 (*) 3.06 Exercisable, December 31, 2019 144,277 4.1 (*) 3.06 (*) Pursuant to the anti-dilution adjustment provisions in outstanding warrants, the per share exercise price was reduced to $4.1, following the issuance of shares of common stock under the Company's at-the-market offering program.

Stock Based Compensation (Table

Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Schedule of stock options granted to non-employees	Year ended 2019 2018 Stock-based compensation expense - Research and development 161 50 Stock-based compensation expense - Sales and marketing 179 3 Stock-based compensation expense - General and administrative 352 949 692 1,002 Year ended 2019 2018 Stock-based compensation expense - equity awards 692 533 Stock-based compensation expense - liability awards - 469 692 1,002
Schedule of outstanding options granted to consultants	Issuance date Options for Weighted Options Expiration April 2012 3,068 NIS 2.25 3,068 April 2022 September 2014 4,000 NIS 24 4,000 September 2020 September 2014 2,334 NIS 30 2,334 September 2020 May 2017 66,667 USD 64 66,667 March 2019- October 2017 5,001 USD 30 5,001 July 2019- February 2018 1,367 USD 27.6 1,367 May 2021- August 2018-December 2018 13,335 USD 14.1 5,419 August 2023- January-June 2019 10,000 USD 15 10,000 January 2020-July 2020 July 2019 5,334 USD 15 1,333 April 2021-July 2023 Total 111,106 99,189
Schedule of share option activity	2019 Number of Weighted Outstanding at January 1 68,637 $ 17.4 Granted 103,601 11.33 Exercised - Expired (8,334 ) Outstanding at year end 163,904 13.87 Vested at year end 101,116 15.43 2018 Number of Weighted Outstanding at January 1 61,703 18.15 Granted 10,635 13.65 Exercised (1,778 ) Expired (1,923 ) Outstanding at year end 68,637 $ 17.4 Vested at year end 54,889 $ 18.15
Stock Option Plan for employees [Member]
Schedule of stock options granted to non-employees	Year ended Year ended 2019 2018 Dividend yield 0 % 0 % Expected volatility 68.9%-94.4 % 84%-102 % Risk-free interest 1.81- 2.56 % 2.02%-2.97 % Contractual term of up to (years) 1-4 1.1-5
Non Employees [Member]
Schedule of stock options granted to non-employees	2019 2018 Dividend yield 0 % 0 % Expected volatility 85.2%-86.33 88.43 % Risk-free interest 1.82-2.13 3.04 % Contractual term of up to (years) 4.95-5.01 4.7-5 Suboptimal exercise multiple (NIS) 5 5

Short Term Loan (Tables)

Short Term Loan (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of assumptions used to measure fair value of warrants	Day of issuance As of December 31 st As of December 31 st Fair Value $ 523 $ 257 $ 63 Strike Price $ 11.25 $ 10.725 $ 4.1 Dividend Yield % - - - Expected volatility 86.73 % 88.96 % 87.12 % Risk free rate 2.11 % 2.51 % 1.64 % Expected term 5 3.8 2.8 Stock Price $ 11.25 $ 11.55 $ 3.32

Sales and Marketing (Tables)

Sales and Marketing (Tables)	12 Months Ended
	Dec. 31, 2019
Sales And Marketing
Schedule of sales and marketing	Year ended December 31, 2019 2018 Salaries 582 163 Consultants and subcontractors 434 218 Marketing 480 144 Share based payments for consultants and employees 179 3 Travel 99 284 Other 155 87 1,929 899

General and Administrative Ex_2

General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
General And Administrative Expenses [Abstract]
Shedule of general and administrative expenses	Year ended December 31, 2019 2018 Salaries 554 617 Professional services 721 813 Share based payments for consultants, directors and employees 352 949 Rent, office expenses and communication 285 194 Insurance 296 149 Travel 66 144 Directors 45 57 Other 268 248 2,587 3,171

Financial Income (Expense), N_2

Financial Income (Expense), Net (Tables)	12 Months Ended
	Dec. 31, 2019
Financial Income Expense Net [Abstract]
Schedule of financial income (expense), net	Year ended A. Financial income December 31, 2019 2018 Revaluation of derivative 8 156 Exchange rate differences - 706 Revaluation investment in marketable securities - 123 Change in fair value of warrants 989 - Other 51 28 1,048 1,013 Year ended B. Financial expense December 31, 2019 2018 Exchange rate differences 357 - Financial expenses from loans - 192 Change in fair value of warrants - 1,587 Revaluation investment in marketable securities 195 - Other 3 28 555 1,807

General (Details)

General (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
General (Textual)
Accumulated deficit	$ 28,514	$ 23,017
Purchasing an interest venture percentage	18.00%
Ventures development period	7 years
Purchasing venture agreement terms	As part of the agreement, the Seller received an option to buy back the Assets for consideration which will reflect the market fair value at that time, on the occurrence of the following events: a) if a motion is filed to liquidate the Company; b) if seven years after signing the agreement, the Company's total accumulated revenues, direct or indirect, from the Venture or the commercialization of the patent will be lower than NIS 3.6 million.

Significant Accounting Polici_4

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2019
Computers and peripheral equipment [Member]
Property and equipment, depreciation rate	33.00%
Leasehold improvements [Member]
Property and equipment, terms	Over the term of the lease or the useful life of the improvements, whichever is shorter
Office furniture and equipment [Member] | Minimum [Member]
Property and equipment, depreciation rate	7.00%
Office furniture and equipment [Member] | Maximum [Member]
Property and equipment, depreciation rate	15.00%

Significant Accounting Polici_5

Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Significant Accounting Policies (Textual)
Severance pay deposit rate	8.33%
Tax benefit, description	Measure the tax benefit as the largest amount that is greater than 50 percent (cumulative basis) likely to be realized upon settlement.
Functional currency reclass amount	$ 328
Right of use assets	$ 966	$ 127

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 1,203	$ 5,140
US Dollars [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	806	4,879
Euro [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	47	4
New Israeli Shekels [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 350	$ 257

Other Receivables and Prepaid_3

Other Receivables and Prepaid Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Other Receivables and Prepaid Expenses [Abstract]
Prepaid expenses and deferred costs	$ 268	$ 130
Government authorities	40	27
Insurance reimbursement		50
Other	13	11
Total	$ 321	$ 218

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cost
Beginning balance	$ 163	$ 135
Additions	103	40
Disposals	(8)
Translation adjustments	13	(12)
Ending balance	263	163
Accumulated Depreciation
Beginning balance	92	68
Additions	30	31
Disposals	(8)
Translation adjustments	8	(7)
Ending balance	122	92
Property and equipment net, carrying amounts	141	71
Office furniture and equipment [Member]
Cost
Beginning balance	28	20
Additions	22	8
Disposals
Translation adjustments	2
Ending balance	52	28
Accumulated Depreciation
Beginning balance	5	3
Additions	3	2
Disposals
Translation adjustments
Ending balance	8	5
Property and equipment net, carrying amounts	44	23
Leasehold improvements [Member]
Cost
Beginning balance	15	17
Additions	55
Disposals	(16)
Translation adjustments	1	(2)
Ending balance	55	15
Accumulated Depreciation
Beginning balance	6	5
Additions	3	2
Disposals	(8)
Translation adjustments	1	(1)
Ending balance	2	6
Property and equipment net, carrying amounts	53	9
Computers and peripheral equipment [Member]
Cost
Beginning balance	120	98
Additions	26	32
Disposals
Translation adjustments	10	(10)
Ending balance	156	120
Accumulated Depreciation
Beginning balance	81	60
Additions	24	27
Disposals
Translation adjustments	7	(6)
Ending balance	112	81
Property and equipment net, carrying amounts	$ 44	$ 39

Leases (Details)

Leases (Details) $ in Thousands	Dec. 31, 2019USD ($)
Leases [Abstract]
2020	$ 135
2021	150
2022	154
2023	162
2024	162
2025	$ 112

Leases (Details 1)

Leases (Details 1) $ in Thousands	Dec. 31, 2019USD ($)
Leases [Abstract]
2020	$ 164
2021	172
2022	162
2023	186
2024	172
2025	115
Thereafter	971
Less imputed interest:	(210)
Total lease liabilities	$ 761

Leases (Details Textual)

Leases (Details Textual) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 31, 2019	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Leases (Textual)
Right-of-use assets		$ 966	$ 127
Operating lease liabilities		$ 761
Leases term, description		These leases generally have terms which range from 1 year to 6 years, and often include one or more options to renew. These renewal terms can extend the lease term from 1 year to 6 years, and are included in the lease term when it is reasonably certain that the Company will exercise the option.
Lease agreement, description	The lease term is for 36 months beginning on August 20, 2019 and ending on August 20, 2022, with an option to extend for an additional 36 months. Monthly rent payments including utilities amounting to approximately NIS 39,000 per month.
Rent expense		$ 174
Right-of-use assets include leasehold improvements		205
Net of amortization		205
Decrease in right to use asset		$ 7
Interest rate used to discount future lease payment		8.69%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands		Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Due from related parties		$ 41	$ 40
Officers [Member]
Related Party Transaction [Line Items]
Due from related parties	[1]	28	26
Directors [Member]
Related Party Transaction [Line Items]
Due from related parties		13	11
Monkeytech [Member]
Related Party Transaction [Line Items]
Due from related parties	[2]		$ 3
[1]	The amount includes the net salary payable.
[2]	The former Chief Technology Officer of the Company, Oded Shoshan, was compensated pursuant to a technology consulting agreement between the Company and Monkeytech Ltd. Mr. Shoshan was the chief executive officer up until April 2019 as well as one of the owners of Monkeytech.

Related Party Transactions (D_2

Related Party Transactions (Details 1) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Controlling shareholder benefits	$ 1,422	$ 1,114
Salaries and related expenses [Member]
Controlling shareholder benefits	904	792
Research and development expenses to subcontractor [Member]
Controlling shareholder benefits		164
Directors [Member]
Controlling shareholder benefits	45	57
Share based payments [Member]
Controlling shareholder benefits	$ 473	$ 101

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Level 1 [Member]
Financial assets
Investment in marketable securities
Financial liabilities
Warrants and derivative
Level 2 [Member]
Financial assets
Investment in marketable securities	26	208
Financial liabilities
Warrants and derivative	328	1,252
Level 3 [Member]
Financial assets
Investment in marketable securities
Financial liabilities
Warrants and derivative

Financial Instruments (Details

Financial Instruments (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Financial Instruments (Textual)
Recognized gain (loss) of marketable securities	$ (192)	$ 123
Fair value	$ 26	$ 208

Taxes on Income (Details)

Taxes on Income (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Israeli subsidiaries [Member]
Effective income tax rate	23.00%	23.00%

Taxes on Income (Details 1)

Taxes on Income (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
U.S	$ (896)	$ (4,131)
Non-U.S. (foreign)	(4,601)	(1,838)
Net loss	$ (5,497)	$ (5,969)

Taxes on Income (Details 2)

Taxes on Income (Details 2) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Operating loss carryforwards	$ 16,451	$ 14,380
Warrants and options	89	60
Marketable securities	375	336
Other temporary differences	295	212
Deferred tax assets before valuation allowance	17,210	14,988
Valuation allowance	(17,210)	(14,988)	$ (14,835)
Net deferred tax asset

Taxes on Income (Details 3)

Taxes on Income (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Balance at beginning of the year	$ 14,988	$ 14,835
Additions in valuation allowance to the income statement	1,211	876
Reductions in valuation allowance due to exchange rate differences and change in tax rate	1,011	(723)
Balance at end of the year	$ 17,210	$ 14,988

Taxes on Income (Details 4)

Taxes on Income (Details 4) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (5,497)	$ (5,969)
Statutory tax rate	21.00%	21.00%
Computed "expected" tax expense	$ 1,154	$ 1,253
Foreign tax rate differences and exchange rate differences	77	38
Nondeductible expenses	(20)	(415)
Change in valuation allowance	(1,211)	(876)
Taxes on income

Taxes on Income (Details Textua

Taxes on Income (Details Textual) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Dec. 22, 2017	Dec. 22, 2016	Dec. 31, 2019
Taxes on Income (Textual)
U.S. federal net operating loss ("NOL") carryforwards			$ 20,262
Corporate tax rate, description		The Knesset plenum passed the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018) – 2016, by which, inter alia, the corporate tax rate would be reduced from 25% to 23% in two steps. The first step was to a rate of 24% as of January 2017 and the second step was to a rate of 23% as of January 2018.	Utilization of the U.S. net operating losses may be subject to substantial limitations due to the change of ownership provisions of the Internal Revenue Code of 1986.
Available carryforward operating tax losses			$ 43,614
Maximum [Member]
Taxes on Income (Textual)
Effective income tax rate	35.00%
Minimum [Member]
Taxes on Income (Textual)
Effective income tax rate	21.00%
Israeli [Member]
Taxes on Income (Textual)
Available carryforward operating tax losses			$ 53,028

Shareholders' Equity (Details)

Shareholders' Equity (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)$ / shares
Warrant [Member]
Fair Value | $	$ 33
Strike Price	$ 4.1
Dividend Yield %
Expected volatility	94.30%
Risk free rate	1.64%
Expected term	2 years 11 months 23 days
Stock Price	$ 3.32
Warrant [Member] | Day of issuance [Member]
Fair Value | $	$ 1,625
Strike Price	$ 12.765
Dividend Yield %
Expected volatility	89.50%
Risk free rate	2.26%
Expected term	5 years
Stock Price	$ 10.65
Warrant One [Member]
Fair Value | $	$ 231
Strike Price	$ 4.1
Dividend Yield %
Expected volatility	93.60%
Risk free rate	1.65%
Expected term	3 years 1 month 2 days
Stock Price	$ 3.32
Warrant One [Member] | Day of issuance [Member]
Fair Value | $	$ 2,102
Strike Price	$ 39.75
Dividend Yield %
Expected volatility	96.70%
Risk free rate	2.59%
Expected term	5 years
Stock Price	$ 25.35

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1) - $ / shares		12 Months Ended
		Dec. 31, 2019		Dec. 31, 2018
Number of Warrants
Number of Warrants Outstanding, Beginning balance		144,277		268,329
Number of Warrants, Issued				100,013
Number of Warrants, Expired or exercised				(224,065)
Number of Warrants Outstanding, Ending balance		144,277		144,277
Number of Warrants, Exercisable		144,277
Weighted Average Exercise Price
Weighted Average Exercise Price Outstanding, Beginning balance		$ 31.5		$ 16.5
Weighted Average Exercise Price Outstanding, Ending balance		4.1	[1]	$ 31.5
Warrants Weighted Average Exercise Price, Exercisable	[1]	$ 4.1
Weighted Average Remaining Life in Years
Weighted Average Remaining Life in Years, Outstanding		3 years 22 days		4 years 22 days
Weighted Average Remaining Life in Years, Exercisable		3 years 22 days
[1]	Pursuant to the anti-dilution adjustment provisions in outstanding warrants, the per share exercise price was reduced to $4.1, following the issuance of shares of common stock under the Company's at-the-market offering program.

Shareholders' Equity (Details T

Shareholders' Equity (Details Textual ) - USD ($) $ / shares in Units, $ in Thousands	Sep. 13, 2019	Nov. 30, 2019	Nov. 18, 2019	Feb. 02, 2018	Dec. 22, 2017	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Stockholders' Equity (Textual)
Total consideration								$ 318
Warrants reclassified to additional paid-in-capital								2,260
Warrants reclassified to equity							$ 3,851	411
Common stock issued, shares						87,756
Total consideration from the public offering	$ 5,500
Net of issuance cost						$ 418
Fair value of warrants amount							$ 63	257
Common stock average price						$ 4.77
Gross proceeds from sale of common stock, percent	3.00%
Increase of after deducting legal and other related expenses	$ 266
Reverse stock split			The one-for-fifteen reverse stock split.
Securities Purchase Agreement [Member]
Stockholders' Equity (Textual)
Common stock issued, shares		100,013
Exercise price per shares		$ 4.1
Warrants to purchase		14,633
Reverse stock split		One-for-fifteen reverse stock split.
Warrant [Member]
Stockholders' Equity (Textual)
Total consideration				$ 6,000
Common stock issued, shares				200,000	255,500
Issue options to purchase common stock, Shares				100,013	191,628
Exercise price per shares				$ 39.75	$ 9.75		$ 4.1
Exercise price of warrants					$ 12.765
Total consideration from the public offering					$ 2,490
Net of issuance cost				$ 5,464	2,130
Value of common stock and warrants issued				2,102	1,625
Fair value of warrants amount				$ 3,547	$ 505		$ 231	862
Fair value of warrants							$ 34	$ 124
Warrant term				5 years	5 years
Warrants to purchase								176,995

Stock Based Compensation (Detai

Stock Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 692	$ 1,002
Equity awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	692	533
Liability awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		469
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	161	50
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	179	3
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 352	$ 949

Stock Based Compensation (Det_2

Stock Based Compensation (Details 1)	12 Months Ended
	Dec. 31, 2019$ / sharesshares		Dec. 31, 2019₪ / sharesshares	Dec. 31, 2018$ / shares	Dec. 31, 2017$ / shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options for Common stock	111,106
Weighted Average exercise price per share | $ / shares	$ 4.1	[1]		$ 31.5	$ 16.5
Options exercisable	99,189		99,189
April 2012 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options for Common stock	3,068
Options exercisable	3,068		3,068
Expiration date	April 2022
April 2012 [Member] | NIS [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Weighted Average exercise price per share | ₪ / shares			₪ 2.25
September 2014 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options for Common stock	4,000
Options exercisable	4,000		4,000
Expiration date	September 2020
September 2014 [Member] | NIS [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Weighted Average exercise price per share | ₪ / shares			₪ 24
September 2014 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options for Common stock	2,334
Options exercisable	2,334		2,334
Expiration date	September 2020
September 2014 [Member] | NIS [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Weighted Average exercise price per share | ₪ / shares			₪ 30
May 2017 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options for Common stock	66,667
Weighted Average exercise price per share | $ / shares	$ 64
Options exercisable	66,667		66,667
May 2017 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	March 2019
May 2017 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	March 2020
October 2017 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options for Common stock	5,001
Weighted Average exercise price per share | $ / shares	$ 30
Options exercisable	5,001		5,001
October 2017 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	July 2019
October 2017 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	April 2020
February 2018 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options for Common stock	1,367
Weighted Average exercise price per share | $ / shares	$ 27.6
Options exercisable	1,367		1,367
February 2018 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	May 2021
February 2018 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	February 2023
August 2018-December 2018 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options for Common stock	13,335
Weighted Average exercise price per share | $ / shares	$ 14.1
Options exercisable	5,419		5,419
August 2018-December 2018 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	August 2023
August 2018-December 2018 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	December 2023
January-June 2019 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options for Common stock	10,000
Weighted Average exercise price per share | $ / shares	$ 15
Options exercisable	10,000		10,000
January-June 2019 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	January 2020
January-June 2019 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	July 2020
July 2019 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options for Common stock	5,334
Weighted Average exercise price per share | $ / shares	$ 15
Options exercisable	1,333		1,333
July 2019 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	April 2021
July 2019 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Expiration date	July 2023
[1]	Pursuant to the anti-dilution adjustment provisions in outstanding warrants, the per share exercise price was reduced to $4.1, following the issuance of shares of common stock under the Company's at-the-market offering program.

Stock Based Compensation (Det_3

Stock Based Compensation (Details 2)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Non-Employees [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	68.90%	84.00%
Risk-free interest	1.81%	2.02%
Contractual term of up to (years)	1 year	1 year 1 month 6 days
Non-Employees [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	94.40%	102.00%
Risk-free interest	2.56%	2.97%
Contractual term of up to (years)	4 years	5 years
Stock Option Plan for employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility		88.43%
Risk-free interest		3.04%
Suboptimal exercise multiple (NIS)	5 years	5 years
Stock Option Plan for employees [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	85.20%
Risk-free interest	1.82%
Contractual term of up to (years)	4 years 11 months 12 days	4 years 8 months 12 days
Stock Option Plan for employees [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	86.33%
Risk-free interest	2.13%
Contractual term of up to (years)	5 years 4 days	5 years

Stock Based Compensation (Det_4

Stock Based Compensation (Details 3) - $ / shares	12 Months Ended
	Dec. 31, 2019		Dec. 31, 2018
Number of Warrants
Number of options , Granted			100,013
Weighted average Exercise price
Weighted Average Exercise Price Outstanding, Beginning balance	$ 31.5		$ 16.5
Weighted Average Exercise Price Outstanding, Ending balance	$ 4.1	[1]	$ 31.5
Share Option [Member]
Number of Warrants
Number of options Outstanding, Beginning balance	68,637		61,703
Number of options , Granted	103,601		10,635
Number of options, Exercised			(1,778)
Number of options, Expired	(8,334)		(1,923)
Number of options Outstanding, Ending balance	163,904		68,637
Number of options, Vested at year end	101,116		54,889
Weighted average Exercise price
Weighted Average Exercise Price Outstanding, Beginning balance	$ 17.4		$ 18.15
Weighted average Exercise price, Granted	11.33		13.65
Weighted Average Exercise Price Outstanding, Ending balance	13.87		17.4
Weighted average Exercise price, Vested at year end	$ 15.43		$ 18.15
[1]	Pursuant to the anti-dilution adjustment provisions in outstanding warrants, the per share exercise price was reduced to $4.1, following the issuance of shares of common stock under the Company's at-the-market offering program.

Stock Based Compensation (Det_5

Stock Based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

12 Months Ended

Jul. 31, 2019

Apr. 30, 2019

Dec. 31, 2018

Aug. 31, 2018

May 31, 2018

Feb. 28, 2018

Jan. 31, 2018

Jan. 23, 2018

Oct. 31, 2017

Aug. 31, 2017

Jul. 31, 2017

Apr. 30, 2017

Mar. 31, 2017

Dec. 31, 2019

Dec. 31, 2018

Stock Based Compensation (Textual)

Stock-based compensation expense

$ 692

$ 1,002

Number of options, Granted

100,013

Stock issued options value

$ 8,648

Common stock shares issued

1,990,159

1,992,243

1,990,159

Cost weighted-average period term

3 years 22 days

Research and Development [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

$ 161

$ 50

Selling and Marketing Expense [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

179

3

General and Administrative Expenses [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

352

949

Employee Stock Option [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

$ 540

$ 139

Number of options, Granted

200,000

103,601

10,635

Unrecognized compensation cost

$ 737

Cost weighted-average period term

2 years 9 months

Employee Stock Option [Member] | Research and Development [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

$ 161

$ 50

Employee Stock Option [Member] | Selling and Marketing Expense [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

168

3

Employee Stock Option [Member] | General and Administrative Expenses [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

211

86

Consultant [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company entered into agreements with three consultants (collectively, the "Consultants") to provide services to the Company including promoting the Company's products and services. For such consulting services, the Company agreed to issue to each of the Consultants options to purchase up to 3,334 shares of the Company's common stock at an exercise price of $30.00 per share. The options vest quarterly in four equal installments and terminate eighteen (18) months from their respective vesting dates. The issuance of the options under the agreement was subject to the increase in the number of shares of the Company's common stock reserved for issuance pursuant to the Company's 2017 Consultant Plan. The increase in reserve pursuant to the Company's 2017 Consultant Plan was approved by the Company's stockholders on February 12, 2018 at the Company's special meeting of stockholders.

Cost of fair value undertaking

Consultant2 [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

0

549

Consultant3 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company engaged a consultant ("Consultant3") to provide services to the Company with respect to financing and strategic advisory for a period of two years. For such consulting services, the Company agreed to pay a monthly retainer and agreed to issue to Consultant3 3,334 shares of the Company common stock and 2,084 shares each quarter thereafter.

Stock-based compensation expense

$ 48

$ 192

Common stock shares issued

10,417

10,417

10,417

Consultant4 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company engaged a consultant ("Consultant4") to provide services to the Company with respect to business consulting for a period of one year. For such consulting services, the Company issued to Consultant4 10,000 stock options to purchase up to 10,000 shares of the Company's common stock at an exercise price of $30 per share. The options vest in four equal installments on a quarterly basis and terminate 18 months from each vesting date. During the year 2018, costs in sum $70 were recorded as stock-based liability- awards. In addition, in 2018, an amount of $7 was classified to equity following the adoption of ASU 2018-07, see also note 2 j. As of December 31, 2019, the options were not exercised and expired.

Consultant5 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company engaged a consultant ("Consultant5") to provide services to the Company with respect to various services including corporate planning, financial public relations, business strategy and shareholders relations. For such consulting services, the Company agreed to issue to Consultant5 options to purchase 66,667 shares of the Company's common stock at an exercise prices of $15.00 per share exercisable until April 30, 2018 and 15,334 options to purchase common stock at exercise price of $37.5 per share exercisable until December 31, 2018. The board approved the issuance on August 31, 2017.

Amendment to consulting agreement

$ 53,334

Consulting agreement options, per share

$ 15

Consultant6 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company entered into a twelve-month agreement with a consultant ("Consultant6") to provide strategic consulting and investor relations services. Pursuant to the terms of the agreement, the Company agreed to pay a monthly fee of $5 and to issue to Consultant6 6,600 shares of common stock of the Company in three tranches of 2,200 each, with each tranche vesting on the first day of January, April and August 2018. The board approved the issuance on February 14, 2018.

Stock-based compensation expense

$ 0

$ 112

Consideration for the services of common stock

6,600

Consultant7 [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

0

77

Consideration for the services of common stock

1,000

3,334

Three Consultants [Member]

Stock Based Compensation (Textual)

Equity adoption value

60

Three Consultants [Member] | Liability Awards [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

0

73

Consultant8 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company entered into an agreement with a consultant ("Consultant8") to provide services to the Company including improving the Company's products and services. Pursuant to such agreement and in consideration for such consulting services, the Company agreed to issue to Consultant8 options to purchase up to 367 shares of the Company's common stock at an exercise price of $21.15 per share. The options are fully vested and shall terminate five years after the grant date.

Number of options, Granted

367

Exercise price

$ 21.15

Equity adoption value

4

Consultant8 [Member] | Liability Awards [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

0

5

Consultant9 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company entered into an agreement with a consultant ("Consultant9") to provide services to the Company including marketing and improving the implementation of the technology with potential customers. Pursuant to such agreement and in consideration for such consulting services, the Company agreed to issue to Consultant9 options to purchase up to 1,000 shares of the Company's common stock at an exercise price of $30 per share. The options shall vest quarterly in three equal installments and shall terminate five years after the grant date.

Number of options, Granted

1,000

Exercise price

$ 30

Equity adoption value

7

Consultant9 [Member] | Equity Awards [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

0

1

Consultant9 [Member] | Liability Awards [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

0

4

Consultant10 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company entered into an agreement with a consultant ("Consultant10") to provide services to the Company including promoting the Company's products and services. Pursuant to such agreement and in consideration for such consulting services, the Company agreed to issue to Consultant10 options to purchase up to 3,334 shares of the Company's common stock at an exercise price of $15.00 per share. The options shall vest quarterly in eight equal installments and shall terminate five years after the grant date. The board approved the issuance on August 15, 2018.

Number of options, Granted

3,334

Exercise price

$ 15

Equity adoption value

3

Consultant10 [Member] | Equity Awards [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

0

6

Consultant10 [Member] | Liability Awards [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

22

$ 2

Consultant11 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company entered into an agreement with a consultant ("Consultant11") to provide services to the Company including promoting the Company's products and services. Pursuant to such agreement and in consideration for such consulting services, the Company agreed to issue to Consultant11 options to purchase up to 3,334 shares of the Company's common stock at an exercise price of $11.325 per share. The options shall vest quarterly in four equal installments and shall terminate five years after the grant date. The board approved the issuance on December 27, 2018.

Number of options, Granted

3,334

Exercise price

$ 11.325

$ 11.325

Consultant11 [Member] | Equity Awards [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

$ 29

$ 1

Consultant12 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company entered into an agreement with a consultant ("Consultant12") to provide services to the Company including promoting the Company's products and services via potential sources of media. Pursuant to said agreement and in partial consideration for such consulting services, the Company agreed to issue to Consultant12 a warrant to purchase up to 3,334 shares of the Company's common stock upon execution of the agreement and after six months, a further warrant to purchase 6,667 shares of the Company's common stock. The warrants are exercisable at $15.00 per share and have a term of 12 months from the date of issuance.

Stock-based compensation expense

$ 42

Consultant13 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company entered into a twelve month agreement with a consultant ("Consultant13") to provide services to the Company including assisting the Company to promote, market and sell the Company's technology to potential customers. Pursuant to said agreement and in partial consideration for such consulting services, the Company agreed to issue to Consultant13 options to purchase up to 2,667 shares of the Company's common stock upon execution of the agreement. The options are exercisable at $15.00 per share and shall vest in 4 equal installments every three months starting July 2019. Unexercised options shall expire 2 years from the effective date.

Consultant13 [Member] | Equity Awards [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

8

Consultant14 [Member]

Stock Based Compensation (Textual)

Consulting agreement, description

The Company entered into a three year agreement with a consultant ("Consultant14") to provide services to the Company including assisting the Company to promote, market and sell the Company's technology to potential customers. Pursuant to such agreement and in partial consideration for such consulting services, the Company agreed to issue to Consultant14 options to purchase up to 2,667 shares of the Company's common stock upon execution of the agreement. The options are exercisable at $15.00 per share and shall vest in 3 equal installments every twelve months starting July 2019. Unexercised options shall expire 4 years from the effective date.

Consultant14 [Member] | Equity Awards [Member]

Stock Based Compensation (Textual)

Stock-based compensation expense

$ 3

Short Term Loan (Details)

Short Term Loan (Details) - Short-term Debt [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value	$ 63	$ 257
Strike Price	$ 4.1	$ 10.725
Dividend Yield %
Expected volatility	87.12%	88.96%
Risk free rate	1.64%	2.51%
Expected term	2 years 9 months 18 days	3 years 9 months 18 days
Stock Price	$ 3.32	$ 11.55
Date of Issuance [Member]
Fair Value	$ 523
Strike Price	$ 11.25
Dividend Yield %
Expected volatility	86.73%
Risk free rate	2.11%
Expected term	5 years
Stock Price	$ 11.25

Short Term Loan (Details Textua

Short Term Loan (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			12 Months Ended
	Nov. 18, 2019	Feb. 28, 2018	Oct. 26, 2017	Dec. 31, 2019	Dec. 31, 2018
Short Term Loan (Textual)
Private placement transaction for total consideration			$ 1,200
Total Consideration					$ 318
Warrants to purchase of common stock, Shares	29,633		59,264		29,633
Warrants exercisable price per share	$ 4.1
Warrants measured at fair value				$ 63	$ 257
Financial expenses from loans		$ 192
Repayment of principal amount			$ 1,333
Warrants reclassified to equity				$ 3,851	$ 411
Reverse stock split, description	The one-for-fifteen reverse stock split.

Contingencies and Commitments (

Contingencies and Commitments (Details Textual) - USD ($) $ in Thousands	Feb. 07, 2020	Aug. 07, 2018	Aug. 02, 2018	Nov. 30, 2019	Oct. 01, 2019	Jan. 22, 2019
Contingencies and Commitments (Textual)
Plaintiff damage, description			North Empire filed a Summons with Notice against the Company, also in the same Court, in which they allege damages in an amount of $11.4 million arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by the Company against them, alleging that the Company failed to deliver stock certificates to North Empire causing damage to North Empire in the amount of $10,958,589. North Empire also filed a third-party complaint against the Company's CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, the Company filed a reply to North Empire's counterclaims. On November 15, 2018, the Company's CEO and now former Chairman of the Board filed a motion to dismiss North Empire's third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint The parties are now engaging in discovery in connection with the claims and counterclaims. The Company believes it is more likely than not that the counterclaims will be denied.
Seeking damages amount		$ 616,000	$ 11,400
Nasdaq capital market, description						The Company was notified by the Nasdaq Stock Market, LLC ("Nasdaq") that the Company was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The notification provided that the Company had 180 calendar days, or until July 22, 2019, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The Company did not regain compliance with the Rule by July 22, 2019 and, as a result, on July 23, 2019, the Company received notice from the Staff that, based upon the Company's continued non-compliance with the Rule, the Staff had determined to delist the Company's common stock from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the "Panel"). The hearing occurred on September 19, 2019.
Lease agreement, description					The Panel granted the Company's request for continued listing of the Company's common stock on the Nasdaq Capital Market pursuant to an extension through January 20, 2020, subject to the condition that the Company regain compliance with the Bid Price Rule by such date and that the Company demonstrate compliance with all requirements for continued listing on the Nasdaq. Previously, on August 5, 2019, at the annual meeting of the Company's stockholders, discretionary authority was granted to the Company's board of directors to effect a reverse stock split at any time until August 5, 2020 at a ratio within the range from one for two up to one for thirty.
Nasdaq non-compliance, description				The Company received formal notice from Nasdaq that the Company's non-compliance with the minimum $2.5 million stockholders' equity requirement, as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Rule"), as of September 30, 2019, could serve as an additional basis for delisting. In accordance with the Nasdaq Listing Rules, the Company has been granted the opportunity and plans to timely present its plan to regain compliance with the Stockholders' Equity Rule for the Panel's consideration.
Subsequent Event [Member]
Contingencies and Commitments (Textual)
NASDAQ Staff compliance, description	The Company received the formal decision of the (Panel), in which the Panel determined that the Company has evidenced full compliance with the minimum $1.00 per share bid price requirement, and granted the Company's request for continued listing on Nasdaq pursuant to an extension, through May 18, 2020, to demonstrate compliance with the minimum $2.5 million stockholders' equity requirement. As previously disclosed, on November 19, 2019, the Company received formal notice from Nasdaq that it did not satisfy the Stockholders' Equity Rule as of September 30, 2019. In response, the Company requested a hearing before the Panel to present its plan to regain compliance with the rule. The Panel's February 7, 2020 decision follows such hearing.

Sales and Marketing (Details)

Sales and Marketing (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total sales and marketing	$ 1,929	$ 899
Salaries [Member]
Total sales and marketing	582	163
Consultants and subcontractors [Member]
Total sales and marketing	434	218
Marketing [Member]
Total sales and marketing	480	144
Share based payments for consultants and employees [Member]
Total sales and marketing	179	3
Travel [Member]
Total sales and marketing	99	284
Other [Member]
Total sales and marketing	$ 155	$ 87

General and Administrative Ex_3

General and Administrative Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
General and administrative expenses	$ 2,587	$ 3,171
Salaries [Member]
General and administrative expenses	554	617
Professional services [Member]
General and administrative expenses	721	813
Share based payments for consultants, directors and employees [Member]
General and administrative expenses	352	949
Rent, office expenses and communication [Member]
General and administrative expenses	285	194
Insurance [Member]
General and administrative expenses	296	149
Travel [Member]
General and administrative expenses	66	144
Directors [Member]
General and administrative expenses	45	57
Other [Member]
General and administrative expenses	$ 268	$ 248

Financial Income (Expense), N_3

Financial Income (Expense), Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Financial income
Revaluation of derivative	$ 8	$ 156
Exchange rate differences		706
Revaluation investment in marketable securities		123
Change in fair value of warrants	989
Other	51	28
Financial income	1,048	1,013
Financial expense
Exchange rate differences	357
Financial expenses from loans		192
Change in fair value of warrants		1,587
Revaluation investment in marketable securities	195	(123)
other	3	28
Financial expense	$ 555	$ 1,807

Events Subsequent to the Bala_2

Events Subsequent to the Balance Sheet (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 15, 2020	Dec. 31, 2019	Dec. 31, 2018
Events Subsequent to The Balance Sheet (Textual)
Issuance of common stock		1,992,243	1,990,159
Subsequent Event [Member]
Events Subsequent to The Balance Sheet (Textual)
Issuance of common stock	514,801
Warrants to purchase	514,801
Exercise price	$ 3.76
Gross proceeds	$ 2,000
Net proceeds	$ 1,700
Warrants term	5 years 6 months